| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Endocrine System |
Recent Updates
Recently added Catalysts
Neurocrine Biosciences, Inc.$177.11
-3.55 (-1.97%)
B 67Pipeline Score Overvalued Biotech · Commercial
Market Cap
15.76 B
EPS
6.70
P/E Ratio
24.09 $
Value Trade
318.53 M
SEC Financials
Q1 2026Dilution Risk
Revenue
814.50 M
R&D Expenses
296.20 M
Operating CF
145.80 M
Total Assets
4.91 B
Total Liabilities
1.50 B
Equity
3.41 B
D/E Ratio
12,345
-0.96 %
Week
19.39 %
1 Month
21.05 %
3 Month
11.74 %
6 Month
64.72 %
5 Year
1,205.83 %
All Time
Cash Data
Cash Position
1.32 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
1.05 M
52 Week Range
119.62 - 162.39
% held by Insiders
1.74 %
% held by Institutions
101.82 %
Enterprise Value
14.85 B
Total Shares
100.55 M
Short %
5.85 %
Float Shares
94.62 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Neurocrine Biosciences, Inc.
1178Total events
10Upcoming
307Tier-1 (high impact)
2010 – 2027Coverage
Upcoming catalysts 10
Event history 1168
Jul 1, 2026
▲Trial InitiationCrinecerfontTrial
Initiation of Phase 2 study of crinecerfont in pediatric patients under 4 years old with classic CAH
classic congenital adrenal hyperplasiasource ↗
Jul 1, 2026
▲Enrollment CompleteCrinecerfontTrial
Target enrollment achieved for Phase 2 study in EU in children from birth to under 2 years
classic congenital adrenal hyperplasiasource ↗
Jun 15, 2026
▲Late-BreakerPresentation
Late-breaking data at ENDO 2026 showing durable improvements after resuming VYKAT XR following randomized withdrawal
Prader-Willi syndromesource ↗
Jun 15, 2026
▲Oral PresentationPresentation
Oral presentation of Study C614 results at ENDO 2026
Prader-Willi syndromesource ↗
Jun 15, 2026
▲Poster PresentationPresentation
Poster: VYKAT XR Outcomes Compared to Real-World Data from PATH for PWS Natural History Study (HQ-CT Analysis)
Prader-Willi syndromesource ↗
Jun 15, 2026
▲Oral PresentationCRENESSITYApprovedPresentation
First retrospective case series of CRENESSITY in patients with classic CAH due to 11β-hydroxylase deficiency presented at ENDO 2026
classic congenital adrenal hyperplasia due to 11β-hydroxylase deficiencysource ↗
Jun 15, 2026
◆Poster PresentationCRENESSITYApprovedPresentation
Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog Registry
classic congenital adrenal hyperplasiasource ↗
Jun 15, 2026
◆Oral PresentationPresentation
Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic CAH: Cox Proportional Hazards Analysis (Rapid Fire #ORF32-02 and Poster #MON-495)
classic congenital adrenal hyperplasiasource ↗
Jun 15, 2026
◆Poster PresentationPresentation
Modified Delphi Panel of U.S. Endocrinologists to Align on Minimum Clinically Important Difference in Glucocorticoid Dose and Other Key Considerations in Classic CAH (Poster #SAT-459)
classic congenital adrenal hyperplasiasource ↗
Jun 15, 2026
◆Oral PresentationPresentation
Impact of Long-Term Diazoxide Choline Extended-Release Treatment and the Prader-Willi Syndrome Profile Questionnaire
Prader-Willi syndromesource ↗
Jun 15, 2026
◆Poster PresentationPresentation
Impact of Long-Term Diazoxide Choline Extended-Release Treatment and the Prader-Willi Syndrome Profile Questionnaire
Prader-Willi syndromesource ↗
Jun 14, 2026
◆Oral PresentationCRENESSITYApprovedPresentation
Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog Registry
classic congenital adrenal hyperplasiasource ↗
Drug Pipeline Intelligence
B67
Pipeline Score $7.6B
Pipeline ValueOvervalued
Valuation Signal29
Drugs Scored0.5x
rNPV / MCap Top 93%
Mid Cap (rank 65 of 911)
Percentile RankNeurocrine Biosciences, Inc. holds a solid B-grade pipeline (67/100), with $9.0B risk-adjusted pipeline value, led by NBI-6024 in Type 1 Diabetes Mellitus (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NBI-6024 Small molecule | Type 1 Diabetes Mellitus | Phase 1 | NCT00873561 | 14% | $2.1B | COMPLETED | 188 | - | - | Jul 1, 2006 | - | Apr 1, 2009 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VYKAT XR | Prader-Willi syndrome | Phase 3 | 2026-06-15 | 6.2 points at Year 1; 6.5 points at Year 2; 6.2 points at Year 3; -2.5 in anxiety; -2.4 in rigidity/irritability; -2.3 in compulsivity; -2.1 in aggressive behaviors; -1.5 in disordered thinking; -1.1 in depression Read More | Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period Soleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment ... Read More | |
VYKAT XR | Prader-Willi syndrome | Phase 3 | 2026-06-15 | 6.2 points at Year 1; 6.5 points at Year 2; 6.2 points at Year 3; -2.5 in anxiety; -2.4 in rigidity/irritability; -2.3 in compulsivity; -2.1 in aggressive behaviors; -1.5 in disordered thinking; -1.1 in depression Read More | Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period Soleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment ... Read More | |
VYKAT XR | Prader-Willi syndrome | Phase 3 | 2026-06-15 | 6.2 points at Year 1; 6.5 points at Year 2; 6.2 points at Year 3; -2.5 in anxiety; -2.4 in rigidity/irritability; -2.3 in compulsivity; -2.1 in aggressive behaviors; -1.5 in disordered thinking; -1.1 in depression Read More | Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period Soleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment ... Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NBIX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NBIX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NBIX▼ -2%today
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
Neurocrine Biosciences has announced a conference call and webcast to discuss its second quarter 2026 financial results. Scheduled for July 30, 2026, the call will begin at 1:30 p.m. PT. The company aims to provide updates on its financial performance and ongoing projects, showcasing its commitment to addressing neurological and psychiatric disorders.
Read more →NBIXNeurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences has launched a Phase 2 clinical trial for crinecerfont, targeting children under 4 years with classic congenital adrenal hyperplasia (CAH). The study aims to evaluate the drug's safety and tolerability in a vulnerable population often reliant on high glucocorticoid doses. This initiative reflects the company's commitment to improving treatment options for young patients with CAH.
Read more →NBIXNeurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Neurocrine Biosciences presented a retrospective case series at ENDO 2026, showcasing the effects of CRENESSITY (crinecerfont) in patients with classic congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. The study revealed substantial reductions in adrenal hormone levels and glucocorticoid doses among patients. This case series provides preliminary insights into the treatment of this rare condition, emphasizing the need for further research.
Read more →NBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences presented two-year data on CRENESSITY (crinecerfont) at ENDO 2026, showing positive growth outcomes in pediatric patients with classic congenital adrenal hyperplasia (CAH). The study indicated slowed bone age progression and improved predicted adult height. Caregiver surveys revealed universal satisfaction and optimism regarding the treatment's impact on children's quality of life.
Read more →NBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences presented new data from the Phase 3 CAHtalyst Adult study at ENDO 2026, showing that CRENESSITY (crinecerfont) significantly improved cardiometabolic outcomes and reduced glucocorticoid doses in adults with classic congenital adrenal hyperplasia (CAH). Over two years, participants experienced weight loss, improved insulin resistance, and enhanced bone health. Patient surveys indicated high satisfaction and improved quality of life.
Read more →NBIXSoleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period Soleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment ...
Soleno Therapeutics, a Neurocrine Biosciences company, presented significant new data at ENDO 2026 regarding VYKAT XR (diazoxide choline) for treating hyperphagia in individuals with Prader-Willi syndrome. The results reveal that patients resuming treatment after a 16-week randomized withdrawal saw continued improvements in hyperphagia and behavioral symptoms. The data, derived from a comprehensive Phase 3 study, showcases that VYKAT XR provides durable benefits and statistically significant enhancements compared to a natural history control group. The drug has a history of FDA approval and is available for patients aged four and older with Prader-Willi syndrome.
Read more →NBIXNeurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
Neurocrine Biosciences presented new data showing that nearly all individuals with intellectual and developmental disabilities experienced improvements in tardive dyskinesia severity after treatment with INGREZZA. The data, reported at a conference, highlighted rapid improvements in both TD symptoms and overall functional status, including socio-emotional outcomes. Clinicians noted significant burdens associated with TD, emphasizing the need for better recognition and treatment.
Read more →NBIXNeurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
Neurocrine Biosciences presented new data from the KINECT®4 trial showing that 94% of patients with tardive dyskinesia treated with INGREZZA (valbenazine) experienced either symptomatic remission or clinically meaningful improvements. Additionally, a claims analysis revealed a high prevalence of hepatic risk factors among these patients, emphasizing the need for careful treatment decisions. INGREZZA remains the only VMAT2 inhibitor approved for use in patients with hepatic impairment.
Read more →NBIX▲ +6.6%on this newsshared move
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026 Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to ...
Neurocrine Biosciences announced it will present new analyses of two-year outcomes for CRENESSITY (crinecerfont) in classic congenital adrenal hyperplasia (CAH) at ENDO 2026. This will cover both adult and pediatric populations, demonstrating sustained results related to androgen control and glucocorticoid exposure. The findings are expected to reinforce CRENESSITY's role as a new standard of care in managing CAH-related complications. Presentations will occur from June 13-16 in Chicago and focus on multiple clinical and patient-reported endpoints.
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Investor Conferences in June
Neurocrine Biosciences, Inc. announced its participation in two upcoming investor conferences in June 2026. The events include a fireside chat at the William Blair 46th Annual Growth Stock Conference and another at the Goldman Sachs 47th Annual Global Healthcare Conference. Webcasts of these presentations will be available on the company's website.
Read more →NBIXNeurocrine Biosciences Completes Acquisition of Soleno Therapeutics Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the...
Neurocrine Biosciences has successfully completed its acquisition of Soleno Therapeutics, enhancing its portfolio with VYKAT XR, the first approved treatment for hyperphagia in Prader-Willi syndrome. The acquisition, valued at $2.9 billion, aims to address significant unmet needs in the rare disease community. VYKAT XR is now commercially available following its FDA approval in March 2025.
Read more →NBIXNeurocrine Biosciences Completes Acquisition of Soleno Therapeutics Strengthens Neurocrine's rare disease portfolio with VYKAT XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recen
Neurocrine Biosciences has successfully completed its acquisition of Soleno Therapeutics, enhancing its portfolio in the treatment of rare diseases. This acquisition includes VYKAT XR, the only FDA-approved medication specifically for hyperphagia in individuals with Prader-Willi syndrome. With the total equity value of the transaction estimated at $2.9 billion, Neurocrine aims to expand access to this critical treatment for patients in need. The transaction represents a step forward in Neurocrine's mission to provide impactful therapies for unmet medical needs.
Read more →NBIXNeurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from a clinician survey highlighting the functional impact...
Neurocrine Biosciences presented new data highlighting the positive effects of INGREZZA (valbenazine) on patients with mild tardive dyskinesia during the American Psychiatric Association 2026 Annual Meeting. The data, derived from a clinician survey, indicates that almost all patients experienced a reduction in uncontrolled movements, with many seeing improvements in as little as four weeks. Additionally, the treatment contributed to enhancements in patients' functional status and independence in daily activities. This research adds to the growing evidence supporting the effectiveness of INGREZZA in treating tardive dyskinesia symptoms.
Read more →NBIXNeurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences has published the first peer-reviewed expert recommendations for glucocorticoid dose reduction in patients with classic congenital adrenal hyperplasia treated with CRENESSITY (crinecerfont). This publication, featured in The Journal of Clinical Endocrinology & Metabolism, aims to address a critical unmet need as the drug's use expands among both pediatric and adult patients.
Read more →NBIX▲ +8.9%on this newsshared move
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
Neurocrine Biosciences reported a strong first quarter for 2026, with net product sales reaching $811 million, a 44% increase year-over-year. The company announced its agreement to acquire Soleno Therapeutics, which includes the treatment VYKATTMXR for hyperphagia in Prader-Willi Syndrome. Additionally, Neurocrine initiated a Phase 2 clinical study for NBI-1117570 in adults with schizophrenia and reaffirmed its full-year sales guidance for INGREZZA.
Read more →NBIXNeurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
Neurocrine Biosciences, Inc. announced its participation in the Bank of America Health Care Conference 2026, scheduled for May 12, 2026. The event will feature executives from the company presenting at 11:20 a.m. Pacific Time. A webcast of the presentation will be available on the company's website, with a replay accessible for one month post-event.
Read more →NBIXNeurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
Neurocrine Biosciences has released survey results indicating that tardive dyskinesia significantly affects employment and daily activities. The survey, conducted during Tardive Dyskinesia Awareness Week, shows that many individuals with TD quit their jobs due to symptoms. The findings underscore the need for increased awareness, early diagnosis, and appropriate treatment options for those affected.
Read more →NBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences presented two-year data from the Phase 3 CAHtalyst Pediatric study, showing that CRENESSITY (crinecerfont) effectively controls androgen levels and reduces glucocorticoid exposure in children with classic congenital adrenal hyperplasia. The study demonstrated significant clinical improvements, including better body mass index and insulin resistance outcomes. The treatment was well tolerated, with no new safety concerns reported.
Read more →NBIXNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
Neurocrine Biosciences has initiated a Phase 1 clinical study for NBIP-'2118, a novel CRF2 receptor agonist aimed at treating obesity. This investigational therapy is designed to promote weight loss while preserving lean mass, addressing limitations of existing treatments. Initial safety and tolerability data are expected in 2027, as part of a broader obesity strategy that includes additional investigational compounds.
Read more →NBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia At two years, 60% of patients who were overweight or obese at baseline experienced clinically meaningful improvements in body mass index, and 61% of...
Neurocrine Biosciences presented new two-year data for CRENESSITY (crinecerfont) demonstrating effective hormone control in pediatric patients with classic congenital adrenal hyperplasia (CAH). The Phase 3 CAHtalyst Pediatric study revealed significant reductions in key hormonal markers, including adrenocorticotropic hormone (ACTH) and 17-hydroxyprogesterone (17-OHP), along with decreased glucocorticoid doses. Notably, 60% of patients who were overweight or obese showed clinically meaningful improvements in body mass index. These findings highlight the potential of CRENESSITY to significantly enhance treatment outcomes for patients with CAH as they transition into adulthood.
Read more →NBIXNeurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new peer-reviewed research in The Journal of Clinical Psychiatry...
Neurocrine Biosciences has published new peer-reviewed research in The Journal of Clinical Psychiatry, focusing on the Tardive Dyskinesia Impact Scale (TDIS). This publication defines clinically meaningful improvement thresholds for assessing patient experiences with the disorder treated by INGREZZA (valbenazine). It emphasizes both patient-reported outcomes and clinician assessments to better understand the treatment response, enhancing the interpretation of clinical trial results. The findings support the significance of TDIS in characterizing the full burden of tardive dyskinesia and highlight the importance of incorporating patient perspectives in clinical evaluations.
Read more →NBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study...
Neurocrine Biosciences, Inc. presented new two-year data from the Phase 3 CAHtalyst Adult study at the American Association of Clinical Endocrinology 2026 Annual Meeting. The findings indicate sustained reductions in glucocorticoid doses among adults with classic congenital adrenal hyperplasia treated with CRENESSITY (crinecerfont). Notably, about 70% of participants achieved doses within the physiologic range, with no worsening of androgen control. The data supports the viability of CRENESSITY as a long-term treatment option.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
Neurocrine Biosciences has scheduled a conference call and webcast for its first quarter 2026 financial results on May 5, 2026. The event will take place at 1:30 p.m. PT and will be accessible via the company's website. A replay will be available shortly after the event concludes.
Read more →NBIXNeurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new real-world evidence demonstrating that adult patients with...
Neurocrine Biosciences has announced the presentation of new real-world evidence indicating that adult patients with tardive dyskinesia who receive INGREZZA (valbenazine) capsules exhibit greater treatment persistence than those on AUSTEDO XR (deutetrabenazine). This analysis, the first to compare treatment persistence of these two therapies, reveals significant differences favoring INGREZZA in maintaining therapy without discontinuation. The data presented at the Academy of Managed Care Pharmacy 2026 Annual Meeting highlights the importance of sustained treatment for managing tardive dyskinesia symptoms.
Read more →NBIXNeurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative...
Neurocrine Biosciences has announced its acquisition of Soleno Therapeutics for $53.00 per share, totaling $2.9 billion. This acquisition includes VYKAT XR, the only FDA-approved treatment for hyperphagia in Prader-Willi syndrome (PWS). The deal is expected to enhance Neurocrine's portfolio and revenue growth, leveraging its existing commercial infrastructure.
Read more →NBIXNeurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio VYKAT TM XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and
Neurocrine Biosciences announced its acquisition of Soleno Therapeutics for $2.9 billion, paying $53.00 per share in cash. This acquisition includes VYKAT XR (diazoxide choline), the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, which generated $190 million in revenue in 2025. The transaction aims to enhance Neurocrine's position in endocrinology and rare diseases and is expected to close within 90 days, subject to customary conditions. The integration of VYKAT XR is anticipated to significantly improve patient care and drive financial growth for Neurocrine.
Read more →NBIXNeurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
Neurocrine Biosciences has presented the first expert consensus recommendations for screening, diagnosis, and treatment of tardive dyskinesia (TD) in older adults within long-term care settings. These recommendations, developed by a Delphi panel, aim to address gaps in managing TD in this vulnerable population. Additionally, a post-hoc analysis from the KINECT-PRO study showed significant patient-reported improvements in TD symptoms among those treated with INGREZZA.
Read more →NBIXNeurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
Neurocrine Biosciences has promoted Andrew Ratz, Ph.D., to Chief Technical Operations Officer. In this role, he will oversee global technical development, manufacturing, and supply chain functions. This strategic move aligns with the company's goal to expand its portfolio beyond small molecules into biologics and device-based therapies.
Read more →NBIXNeurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum ...
Neurocrine Biosciences, Inc. has announced its participation in the Stifel 2026 Virtual CNS Forum, scheduled for March 17, 2026. Members of the management team will present details about the company and its initiatives. The event will be accessible via a live webcast on the company's website, with a replay available for a month after the event. Neurocrine Biosciences is focused on developing treatments for complex neurological, psychiatric, endocrine, and immunological disorders.
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Investor Conferences in March
Neurocrine Biosciences, Inc. has announced its participation in several upcoming investor conferences. The management team will present at these events, which will be accessible via live webcasts on the company's website. A replay of the webcasts will be available shortly after each event concludes. The company continues to focus on developing treatments for various neurological and psychiatric disorders.
Read more →NBIX▼ -10.4%on this news
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
Neurocrine Biosciences reported significant growth in its fourth-quarter and full-year 2025 financial results, with net product sales reaching $798.3 million and $2.83 billion, respectively. The company anticipates continued strong sales for INGREZZA in 2026, projecting between $2.7 billion and $2.8 billion. CEO Kyle W. Gano emphasized the company's commitment to sustainable growth and advancing its clinical pipeline.
Read more →NBIXNeurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
Neurocrine Biosciences has initiated a Phase 2 clinical study for NBI-1065890, targeting adults with tardive dyskinesia (TD). This investigational compound is a selective VMAT2 inhibitor designed to offer a differentiated treatment profile. The study will enroll about 100 participants and assess the efficacy and safety of NBI-1065890 compared to a placebo, with results expected to provide insights into its therapeutic potential.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results
Neurocrine Biosciences has announced a conference call and webcast to discuss its fourth quarter and year-end 2025 financial results. The event is scheduled for February 11, 2026, at 1:30 p.m. PT. The webcast will be accessible on the company's website, with a replay available shortly after the event.
Read more →NBIXNeurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
Neurocrine Biosciences presented head-to-head data showing that INGREZZA (valbenazine) capsules exhibit significantly higher VMAT2 target occupancy compared to AUSTEDO XR (deutetrabenazine). The findings, presented at the American College of Neuropsychopharmacology Annual Meeting, suggest that INGREZZA's superior target engagement may contribute to its clinical efficacy in treating tardive dyskinesia and Huntington's disease chorea.
Read more →NBIXNeurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Kyle Gano will lead the presentation, which will be available via webcast. The company focuses on developing treatments for neurological and neuropsychiatric disorders and has a robust pipeline of clinical candidates.
Read more →NBIXNeurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of...
Neurocrine Biosciences has announced that its Phase 3 KINECT-DCP study evaluating valbenazine for treating dyskinetic cerebral palsy did not meet primary or secondary endpoints. This outcome is particularly disheartening as there are currently no approved therapies for this condition. The study was the largest double-blind placebo-controlled trial conducted for dyskinetic cerebral palsy, involving participants aged six to 70 over a 14-week period. Adverse events observed were consistent with the known safety profile of the drug. Full study results are expected to be reported at a future scientific meeting.
Read more →NBIXNeurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
Neurocrine Biosciences announced a transformative R&D strategy aimed at delivering innovative medicines across neuroscience and endocrinology. The company highlighted its late-stage pipeline, including Phase 3 programs for osavampator and direclidine, with topline data expected in 2027. Additionally, Neurocrine is expanding its CRF platform to develop therapies for metabolic diseases, starting with obesity.
Read more →NBIXNeurocrine Biosciences to Host R&D Day on December 16
Neurocrine Biosciences will host its 2025 R&D Day on December 16, 2025, in San Diego. The event will focus on the company's R&D transformation and its expanding neuroscience pipeline. A discussion with Dr. John Krystal from Yale University will be featured. The event will be available via live webcast and archived for later access.
Read more →NBIXNeurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences has published a peer-reviewed narrative review on VMAT2 inhibitors, focusing on INGREZZA (valbenazine) and its unique profile for treating tardive dyskinesia. The review emphasizes the distinct pharmacologic and clinical attributes of INGREZZA compared to other VMAT2 inhibitors. It aims to inform healthcare providers about optimal treatment decisions for patients with this condition.
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Investor Conferences
Neurocrine Biosciences, Inc. announced its participation in upcoming investor conferences, highlighting its commitment to engaging with the investment community. The company focuses on developing treatments for neurological and neuropsychiatric disorders and has a strong pipeline of products in various stages of clinical development. Webcasts of the events will be available on their website.
Read more →NBIXNeurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences announced that its Phase 2 study of NBI-1070770 for major depressive disorder did not meet the primary endpoint compared to placebo. Despite this, the compound was generally well tolerated, and the company plans to further analyze the data for future steps. The study involved 73 adult patients with inadequate responses to prior antidepressants.
Read more →NBIX▼ -6.4%on this news
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
Neurocrine Biosciences reported strong financial results for Q3 2025, with total net product sales reaching $790 million, a 28% increase from the previous year. INGREZZA generated $687 million in sales, while CRENESSITY contributed $98 million in its launch quarter. The company reaffirmed its guidance for INGREZZA sales and is advancing clinical trials for new therapies in major depressive disorder and schizophrenia.
Read more →NBIXNeurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
Neurocrine Biosciences presented a post-hoc analysis from the KINECT 4 study, showing that 48 weeks of treatment with INGREZZA (valbenazine) 40 mg capsules led to significant improvements in tardive dyskinesia symptoms. The findings, shared at the American Psychiatric Nurses Association Conference, confirm the long-term efficacy and safety of the treatment. Participants experienced sustained benefits with manageable side effects.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results
Neurocrine Biosciences has announced a conference call and webcast to discuss its third quarter 2025 financial results, scheduled for October 28, 2025. The event will be accessible via the company's website, with a replay available afterward. Neurocrine focuses on developing treatments for neurological and neuropsychiatric disorders, showcasing its commitment to addressing significant health needs.
Read more →NBIXNeurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
Neurocrine Biosciences has appointed Mike Sibley as Senior Vice President and General Manager of its Neuropsychiatry franchise. With over 20 years of experience, Sibley will lead the sales and marketing strategies for Neurocrine's neuropsychiatry products, including INGREZZA. His appointment is seen as timely as the company seeks to expand its market presence and advance its product pipeline.
Read more →NBIXNeurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
Neurocrine Biosciences presented new data from the KINECT-HD2 study, highlighting the long-term safety and efficacy of INGREZZA (valbenazine) for managing chorea in Huntington's disease. Over three years, patients showed sustained improvements in chorea severity without adverse effects from antipsychotic medications. These findings were shared at the 2025 MDS International Congress.
Read more →NBIXNeurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden
Neurocrine Biosciences presented new data from a post-hoc analysis of the Phase 4 KINECT-PRO study, demonstrating that treatment with INGREZZA (valbenazine) capsules leads to earlier remission of tardive dyskinesia symptoms. The analysis showed significant improvements in patient-reported outcomes, reinforcing the treatment's efficacy. Results were shared at Psych Congress 2025.
Read more →NBIXNeurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
Neurocrine Biosciences announced positive results from its Phase 2 SAVITRI study of osavampator, demonstrating significant improvements in depression severity in adults with major depressive disorder. The study involved 183 participants and showed promising efficacy with once-daily dosing. Osavampator is being developed as a potential adjunctive treatment for patients not adequately responding to existing antidepressants. The company has initiated a Phase 3 registrational program following these encouraging results.
Read more →NBIXNeurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from the Phase 2 SAVITRI study of osavampator in adults...
Neurocrine Biosciences announced that it will present new data from the Phase 2 SAVITRI study of osavampator at Psych Congress 2025. Osavampator is an investigational therapy targeting major depressive disorder in adults who do not respond adequately to traditional antidepressants. The presentation will take place on September 18, and the firm is currently progressing into a Phase 3 study program to further evaluate this treatment's efficacy. Recent findings are seen as a significant development in understanding and addressing major depressive disorder.
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Investor Conferences in September Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at four investor conferences in September. Chief Financial Officer Matt Abernethy, Chief ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced its participation in four investor conferences scheduled for September. Chief Financial Officer Matt Abernethy will represent the company and engage with investors. The webcasts of the presentations will be accessible on the company's website and will be available for replay after the events. Neurocrine is known for its work in neuroscience-focused biopharmaceuticals and currently has a robust pipeline of clinical developments.
Read more →NBIXNeurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday,...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) is set to participate in the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025. Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the event. The conference will be accessible via a live webcast on the company's website, with a replay available approximately one hour after the presentation. Neurocrine focuses on developing treatments for neurological and neuroendocrine disorders and has a robust pipeline in clinical development.
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2025 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025...
Neurocrine Biosciences, Inc. reported its financial results for the second quarter of 2025, achieving total net product sales of $682 million, representing a 17% year-over-year growth. The sales for INGREZZA reached $624 million, leading to an upward adjustment of the company's full-year sales guidance. The company also noted a robust patient demand for CRENESSITY, which contributed $53 million in net product sales during the quarter. CEO Kyle W. Gano stated that the strong financial performance positions the company well for future growth and expansion across its neuropsychiatry pipeline.
Read more →NBIXNeurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from a new analysis using real-world data from CAHtalog®, a comprehensive...
Neurocrine Biosciences presented new analysis results from the CAHtalog® registry at ENDO 2025, indicating that patients with classic congenital adrenal hyperplasia (CAH) often experience high glucocorticoid exposure and suboptimal disease control. The study analyzed data from 98 patients, revealing considerable variability in glucocorticoid treatment regimens and frequent changes in health states. Despite achieving short-term disease control, most patients could not maintain this over time, underscoring the complexities involved in managing CAH effectively.
Read more →NBIXNeurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new one-year data from the CAHtalyst™ Adult study of CRENESSITY®...
Neurocrine Biosciences has presented one-year data from the CAHtalyst Adult study of CRENESSITY (crinecerfont), demonstrating its sustained efficacy in managing adult patients with classic congenital adrenal hyperplasia. The results showed that patients could achieve lower glucocorticoid doses while maintaining necessary hormone levels. This presentation occurred at the ENDO 2025 event held in San Francisco, adding to the growing evidence highlighting the drug's role in treatment. The data supports clinical outcomes that enhance the management of hormonal imbalances associated with the condition.
Read more →NBIXNeurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies...
Neurocrine Biosciences presented data from the Phase 3 CAHtalyst studies at the Endocrine Society's Annual Meeting, indicating improved weight-related outcomes in patients treated with CRENESSITY. The studies demonstrated that CRNESSITY enables meaningful reductions in glucocorticoid doses in both pediatric and adult patients with classic congenital adrenal hyperplasia. Results showed positive trends in key metrics like BMI and insulin resistance. The CAHtalyst studies mark a significant advancement in the treatment standards for this condition.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced a conference call and webcast scheduled for July 30, 2025, to discuss its second quarter financial results. The event will take place at 1:30 p.m. Pacific Time, with access provided through the company's website. A replay of the call will be available for approximately one month after the event. Neurocrine is recognized for its dedication to developing therapies for neurological and neuropsychiatric disorders, showcasing its innovative pipeline and established FDA-approved treatments.
Read more →NBIXNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety,...
Neurocrine Biosciences has commenced a Phase 1 first-in-human clinical study for its investigational compound NBIP-01435, designed as a long-acting corticotropin-releasing factor type 1 receptor antagonist. The study aims to assess the safety and pharmacokinetics among healthy adults, targeting the treatment of congenital adrenal hyperplasia (CAH). This represents a pivotal step in Neurocrine's biologics pipeline, following their recent FDA approval for a new oral therapy for CAH. The research collaboration with Sentia Medical Sciences has enabled the development of this innovative treatment, signaling commitment to expanding therapeutic options for CAH patients.
Read more →NBIXNeurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new patient-reported post-hoc data from the KINECT®-HD study highlighting significant...
Neurocrine Biosciences announced promising results from the KINECT-HD study demonstrating that INGREZZA (valbenazine) significantly reduces cognitive and motor-related burdens in patients with Huntington's disease chorea. The data showed notable improvements in cognitive functions and motor abilities compared to placebo. These findings will be presented at the upcoming Advanced Therapeutics in Movement & Related Disorders Congress. While the outcomes are favorable, treatment-related adverse events must be monitored carefully.
Read more →NBIXNeurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study demonstrating ...
Neurocrine Biosciences has announced new analyses from a Phase 4 study that show significant patient-reported improvements in health-related quality of life among older adults with tardive dyskinesia who continued treatment with INGREZZA. These results were presented at the 2025 AANP National Conference and build upon previous findings, suggesting continued INGREZZA treatment not only improves functional status but also enhances overall quality of life. The study contributes to the growing evidence supporting the effectiveness of INGREZZA in older patients with this often debilitating condition.
Read more →NBIXNeurocrine Biosciences Appoints Lewis Choi as Chief Information Officer Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, ...
Neurocrine Biosciences has appointed Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, who has 25 years of experience in IT and AI, is expected to drive the company's technology vision and strategies. His leadership comes at a significant time for Neurocrine, as they focus on the launch of CRENESSITY and the growth of their product INGREZZA. The company aims to leverage innovative digital solutions to enhance its mission to develop life-changing treatments for patients.
Read more →NBIXNeurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2...
Neurocrine Biosciences has released data from the Phase 4 KINECT-PRO study, indicating that INGREZZA (valbenazine) significantly improves physical, social, and emotional functioning in patients with tardive dyskinesia. The study, which is the first to utilize multiple validated measures for patient-reported outcomes in this context, demonstrated that even individuals with milder symptoms experienced notable improvements. The findings were presented at the 2025 Psych Congress Elevate, emphasizing the study's unique contribution to the understanding of treatment efficacy in tardive dyskinesia management.
Read more →NBIXNeurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with...
Neurocrine Biosciences has presented positive results from a Phase 2 study of NBI-1117568, an investigational oral muscarinic M4 selective agonist for schizophrenia. The study demonstrated significant improvements in symptoms and overall severity, with data indicating the drug's safety and tolerability. A Phase 3 registrational program has been initiated to further assess its efficacy in patients experiencing acute exacerbations of schizophrenia. Adverse events were noted but were similar to those in the placebo group, and the compound showed a potential novel mechanism of action in treating this condition.
Read more →NBIXNeurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study (NCT03891862) ...
Neurocrine Biosciences, Inc. announced promising results from a Phase 4 randomized withdrawal study of INGREZZA® (valbenazine) for patients with tardive dyskinesia. The study demonstrated significant improvements in functional outcomes and quality of life metrics for patients continuing treatment. Findings, presented at the 2025 ISPOR Conference in Montreal, complement previous patient-reported outcomes, reinforcing the drug's efficacy. The positive results suggest INGREZZA can play a crucial role in enhancing daily functions and reducing the impact of tardive dyskinesia on patients' lives.
Read more →NBIXNeurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data from the Phase 3 CAHtalyst™ Pediatric study showing lasting...
Neurocrine Biosciences announced positive results from its Phase 3 CAHtalyst Pediatric study of CRENESSITY, demonstrating long-term reductions in glucocorticoid doses and improvements in clinical outcomes for pediatric patients with classic congenital adrenal hyperplasia. The study involved 103 participants aged 4 to 17 years and showed significant decreases in adrenocorticotropic hormone and androgen levels. CRENESSITY has potential to improve the treatment landscape for managing this condition, although some adverse reactions were noted. The findings will be presented at the Pediatric Endocrine Society 2025 Annual Meeting.
Read more →NBIXNeurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont) Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™...
Neurocrine Biosciences has presented new data from its Phase 3 CAHtalyst studies for CRENESSITY (crinecerfont), a treatment for classic congenital adrenal hyperplasia (CAH). Findings showed significant improvements in glucocorticoid dosing and hormone levels among both pediatric and adult patients. The pediatric study reported no adrenal crises and demonstrated that CRENESSITY led to normal androstenedione levels, while adult males showed enhanced reproductive hormone metrics. Despite some adverse effects, overall results indicate a positive shift in managing CAH.
Read more →NBIXNeurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented today a systematic literature review illustrating the relationship between higher...
Neurocrine Biosciences presented a systematic literature review at the ISPOR Annual Meeting, illustrating the connection between high-dose glucocorticoids and adverse clinical outcomes in patients with congenital adrenal hyperplasia (CAH). The review identifies complications such as decreased bone mineral density and increased insulin resistance associated with high glucocorticoid doses. The findings emphasize the ongoing challenges in managing CAH, revealing a significant clinical burden from long-term glucocorticoid therapy. Encouragingly, the review points to emerging therapeutic options that may reduce reliance on high-dose glucocorticoids.
Read more →NBIXNeurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new results from subgroup analyses of the Phase 3 CAHtalyst™ Pediatric study. The...
Neurocrine Biosciences announced promising results from the Phase 3 CAHtalyst Pediatric study, indicating that CRENESSITY allows pediatric patients with congenital adrenal hyperplasia to reduce glucocorticoid doses while maintaining or improving their androstenedione levels. The study included 103 patients and revealed consistent results across multiple demographic and clinical subgroups. Data, highlighting the potential for improved long-term outcomes and better management of the condition, is set to be presented at the upcoming European Society Congress in 2025. However, patients are still required to continue their glucocorticoid therapy due to the risks associated with adrenal insufficiency.
Read more →NBIX▲ +8.4%on this newsshared move
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in May. Chief Executive Officer Kyle Gano and...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate in two investor conferences in May, allowing for live webcasts that can be accessed via its website. The webcasts will be archived for one month after the events. Neurocrine focuses on developing treatments for neurological and neuropsychiatric disorders, emphasizing its commitment to patient care and innovation in the biopharmaceutical field.
Read more →NBIX▲ +8.4%on this newsshared move
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of ConnectING with Carnie™, a multimedia awareness campaign in partnership...
Neurocrine Biosciences has launched the ConnectING with Carnie™ campaign in partnership with singer Carnie Wilson to raise awareness for tardive dyskinesia (TD). The initiative focuses on empowering individuals affected by TD to share their experiences and seek treatment without fear of stigma. Through multimedia storytelling, the campaign highlights the impact of uncontrollable movements and encourages open discussions about mental health. Carnie Wilson, though not personally affected by TD, advocates for better understanding and treatment options.
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025...
Neurocrine Biosciences, Inc. reported its financial results for the first quarter of 2025, highlighting $545 million in net sales for INGREZZA and $14.5 million for CRENESSITY. The company affirmed its 2025 sales guidance for INGREZZA, projecting a range of $2.5 to $2.6 billion. CEO Kyle Gano expressed optimism over the strong start to the year, emphasizing record patient enrollments and the advancement of key clinical programs. However, the company experienced a significant decline in GAAP net income compared to the previous year.
Read more →NBIXNeurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey conducted by The Harris Poll highlighting the...
Neurocrine Biosciences has released a new survey conducted by The Harris Poll, revealing that tardive dyskinesia (TD) significantly impacts patients' daily lives. The survey, which involved 150 individuals diagnosed with TD, found that a vast majority wished for earlier screening and discussions about treatment options. This release coincides with TD Awareness Week, aiming to shed light on the importance of early detection and management of TD, which affects approximately 800,000 adults in the U.S. The findings highlight the ongoing need for education and resources to support those living with this condition.
Read more →NBIXNeurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and...
Neurocrine Biosciences, Inc. has announced the initiation of a Phase 3 registrational study for NBI-1117568, aimed at treating adults with schizophrenia. Following the promising Phase 2 results reported in August 2024, this global double-blind, placebo-controlled trial seeks to enroll approximately 280 participants. NBI-1117568 is identified as the first investigational oral muscarinic M4 selective agonist specifically targeting schizophrenia, and aims to improve treatment outcomes without the need for combination therapies typically used in current schizophrenia treatments.
Read more →NBIXNeurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a post-hoc analysis from two 48-week studies, the KINECT® 3 extension and...
Neurocrine Biosciences has published a post-hoc analysis demonstrating the long-term safety and efficacy of INGREZZA (valbenazine) for the treatment of tardive dyskinesia in older adults aged 65 and above. The study, published in The Journal of Clinical Psychiatry, analyzed data from two 48-week studies and indicated substantial and sustained improvements in symptoms without new significant adverse events. The findings underscore the treatment's appropriateness for a vulnerable demographic affected by tardive dyskinesia due to antipsychotic use.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2025 financial results conference call and...
Neurocrine Biosciences, Inc. has announced a conference call and webcast scheduled for May 5, 2025, at 1:30 p.m. Pacific Time to discuss its financial results for the first quarter of 2025. The call can be accessed via the company's website, where a replay will be made available shortly after the event. Neurocrine focuses on developing treatments for neurological and neuroendocrine disorders and maintains a robust pipeline of compounds currently in mid- to late-phase clinical development.
Read more →NBIX▼ -7%on this news
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R D expertise in multiple therapeutic are
Neurocrine Biosciences has appointed Dr. Sanjay Keswani as its new Chief Medical Officer, effective June 2, 2025. Dr. Keswani, a seasoned physician-scientist with over 20 years of experience, will lead the company's clinical development efforts. He succeeds Eiry W. Roberts, who will shift to a strategic advisory role after a successful tenure. Dr. Keswani's expertise will enhance Neurocrine's capabilities as the company focuses on advancing its research and development in various therapeutic areas.
Read more →NBIX▼ -7%on this news
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as...
Neurocrine Biosciences has appointed Dr. Sanjay Keswani as Chief Medical Officer, effective June 2, 2025. Dr. Keswani, an experienced physician-scientist with over 20 years in the pharmaceutical industry, will oversee clinical development and medical affairs. He succeeds Dr. Eiry W. Roberts, who will transition to a strategic advisory role.
Read more →NBIXNeurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from a real-world study showing that all patients with...
Neurocrine Biosciences, Inc. presented new findings from a real-world study at the Academy of Managed Care Pharmacy 2025 Annual Meeting, highlighting that all patients with tardive dyskinesia achieved therapeutic doses of INGREZZA (valbenazine) from the start of treatment. The study involved 3,527 patients and demonstrated significant advantages of INGREZZA over other VMAT2 inhibitors, particularly in achieving dosing without the need for titration. This data emphasizes the potential of INGREZZA to reduce treatment complexity and improve patient outcomes.
Read more →NBIXNeurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of...
Neurocrine Biosciences presented new data from the KINECT 4 study showing that a majority of patients treated with INGREZZA (valbenazine) achieved remission of tardive dyskinesia after 48 weeks. The findings, shared at the 2025 Psychiatry Update Conference, emphasize the drug's effectiveness across different psychiatric conditions with minimal adverse effects. The analysis was based on participants who completed the study, demonstrating significant improvements in the Abnormal Involuntary Movement Scale (AIMS) scores.
Read more →NBIXNeurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT®-HD study showcasing significant improvements in chorea across body...
Neurocrine Biosciences, Inc. presented new data from the KINECT-HD study, demonstrating significant reductions in chorea associated with Huntington's disease following treatment with INGREZZA (valbenazine) capsules. The findings indicate substantial improvement in patient symptoms, particularly in limbs that were severely affected. This reinforces earlier results from the study and suggests the potential for enhanced patient quality of life due to symptom alleviation. Secondary endpoints further support the treatment's efficacy; however, common side effects were also noted.
Read more →NBIXNeurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18,...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) is scheduled to participate in the Stifel 2025 Virtual CNS Forum on March 18, 2025, at 1:30 p.m. ET. CEO Kyle Gano and CMO Eiry Roberts will present at the conference, and a live webcast will be available on the company's website. Neurocrine is recognized for its focus on developing treatments for neurological and neuropsychiatric disorders, supported by a diverse portfolio and active pipeline.
Read more →NBIXNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability,...
Neurocrine Biosciences has commenced a Phase 1 clinical study to assess the safety, tolerability, and pharmacokinetics of NBI-1140675, a selective second-generation VMAT2 inhibitor. This investigational compound aims to address neurological and neuropsychiatric conditions. The study reflects Neurocrine's strategy to expand its portfolio of VMAT2 inhibitors, building on past successes like valbenazine. With prior FDA approvals, the firm continues its focus on innovative treatments in the neuroscience space.
Read more →NBIXNeurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and...
Neurocrine Biosciences announced positive top-line results from the KINECT-PRO™ study assessing the effects of INGREZZA® on tardive dyskinesia. The Phase 4 trial showed significant improvements in multiple patient-reported outcome measures, indicating enhanced physical, social and emotional well-being for participants. The study included various patient demographics and reported sustained benefits from the treatment over a period of 24 weeks. Safety and tolerability data aligned with the known profile of INGREZZA, with no new safety concerns raised.
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Investor Conferences in March Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle Gano, Chief...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced its participation in two investor conferences scheduled for March. The events will feature live webcasts accessible on the company's website, offering opportunities for investor engagement. Neurocrine is recognized for its focus on developing treatments for neurological and neuropsychiatric disorders, alongside a strong pipeline of compounds in clinical development.
Read more →NBIXNeurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which...
Neurocrine Biosciences, Inc. has authorized a new share repurchase program allowing for the repurchase of up to $500 million of its shares. This decision aims to balance the return of capital to shareholders while also supporting continued investments in the company's commercial products and R&D pipeline. This new program follows the successful completion of a prior $300 million repurchase initiative. The company remains dedicated to addressing under-served neuropsychiatric and neurological disorders.
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025 INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of...
Neurocrine Biosciences reported strong financial results for the fourth quarter and full year of 2024, with net product sales of INGREZZA reaching $615 million in Q4 and $2.3 billion for the full year, marking substantial growth. The company also launched CRENESSITY, a first-in-class treatment for congenital adrenal hyperplasia. Looking ahead, Neurocrine provided guidance for 2025, expecting net product sales to range from $2.5 to $2.6 billion. Despite a decline in GAAP net income in Q4, the company plans to advance multiple Phase 3 programs starting in the first half of 2025.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results eurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference...
Neurocrine Biosciences, Inc. has announced a conference call and webcast to discuss its fourth quarter and year-end 2024 financial results, scheduled for February 6, 2025. This event highlights the company's transparency and commitment to providing updates to investors. The call will be accessible via their website, with a replay available afterward. Neurocrine focuses on developing treatments for various neurological and neuroendocrine disorders.
Read more →NBIXNeurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational study to evaluate the efficacy, safety and...
Neurocrine Biosciences has launched a Phase 3 registrational study for osavampator, an investigational adjunctive therapy for major depressive disorder (MDD). Previously, the Phase 2 SAVITRI study yielded positive topline results, showcasing osavampator's potential efficacy and safety. This development is critical as MDD affects over 21 million Americans, many of whom struggle with inadequate responses to existing antidepressant treatments. The trial aims to enroll adults with MDD who have not responded adequately to current medications.
Read more →NBIXNeurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653) Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator...
Neurocrine Biosciences has amended its collaboration with Takeda to secure exclusive worldwide rights for osavampator, except in Japan. This strategic move allows Neurocrine to focus on developing the drug for major depressive disorder, with plans to start Phase 3 trials soon. Takeda retains rights in Japan and both companies will share development costs and royalties.
Read more →NBIXNeurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845 TAK-653) - Neurocrine Obtains Exclusive Worldwide Development and Commercia
Neurocrine Biosciences has amended its collaboration agreement with Takeda to develop and commercialize osavampator, obtaining exclusive rights outside Japan. The agreement streamlines collaboration, allowing Neurocrine to focus on the drug's development while Takeda retains rights in Japan. Following a successful End-of-Phase 2 meeting with the FDA, Neurocrine plans to initiate a Phase 3 program for osavampator, which is an investigational treatment for patients with major depressive disorder who have not responded to prior therapies.
Read more →NBIXAndrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice President of Drug...
Neurocrine Biosciences has appointed Andrew Ratz, Ph.D. as Senior Vice President of Drug Development, Delivery and Device. With 28 years of experience at Eli Lilly, where he oversaw the development of over 25 products, Ratz is expected to enhance Neurocrine's R&D capabilities. His expertise in drug delivery systems aligns with the company's goals of developing innovative treatments for patients with significant needs. This leadership change occurs during an important phase for the company, as it seeks to advance its research portfolio and deliver impactful therapies.
Read more →NBIXNeurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The...
Neurocrine Biosciences has announced the publication of a special supplement in The Journal of Clinical Endocrinology & Metabolism focusing on classic congenital adrenal hyperplasia (CAH). This collection of eight reviews highlights the complex challenges in managing CAH and discusses innovative treatments like CRENESSITY, which targets excess hormone production without high-dose glucocorticoids. The aim is to provide updated insights to healthcare providers, ultimately enhancing clinical practice and patient care related to CAH.
Read more →NBIXNeurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a narrative review discussing the challenges of traditional treatment of...
Neurocrine Biosciences announced the publication of a review in Expert Review of Endocrinology & Metabolism, addressing challenges in treating classic congenital adrenal hyperplasia (CAH) using glucocorticoids (GCs). The review discusses the potential benefits of introducing novel non-GC mechanisms, which could allow for reduced GC dosing and lower the risks of complications associated with high-dose treatments. The approval of CRENESSITY, a new medication that directly targets hormone imbalances in CAH, represents a significant advancement in the management of this condition.
Read more →NBIXNeurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on Monday...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 8:15 a.m. PT in San Francisco. CEO Kyle Gano will lead the presentation, which will be accessible via a live webcast. The company has a diverse portfolio of FDA-approved treatments and is dedicated to developing therapies for complex neurological and neuroendocrine disorders. Replays of the presentation will be available for one month on their website.
Read more →NBIXNeurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced CRENESSITY™ (crinecerfont) is now commercially available in the United States. CRENESSITY ...
Neurocrine Biosciences has announced the commercial availability of CRENESSITY (crinecerfont) in the U.S. for patients with classic congenital adrenal hyperplasia (CAH). This first-in-class treatment allows for lower glucocorticoid doses while effectively managing androgen levels. The company is providing extensive support through PANTHERx Rare pharmacy and Neurocrine Access Support.
Read more →NBIXNeurocrine Biosciences Announces Commercial Availability of CRENESSITY (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia CRENESSITY, a First-in-Class Treatment for Classic Congenital Adre
Neurocrine Biosciences has announced the commercial availability of CRENESSITY (crinecerfont) in the U.S. for both children and adults with classic congenital adrenal hyperplasia (CAH). The treatment has been approved by the FDA and is designed to work alongside glucocorticoid replacement therapy by effectively controlling androgen levels. CRENESSITY represents a significant advancement as it is the first therapy to allow patients to reduce glucocorticoid doses while managing their androgen levels effectively. The company is also providing comprehensive patient support through specialized pharmacists and financial assistance programs.
Read more →NBIXNeurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITY™ (crinecerfont) capsules...
Neurocrine Biosciences has received FDA approval for CRENESSITY, a first-in-class treatment for children and adults with classic congenital adrenal hyperplasia (CAH). This medication is designed to reduce excess adrenocorticotropic hormone and adrenal androgens, potentially allowing for reduced use of glucocorticoids. The approval follows the largest clinical trial program for CAH, demonstrating that CRENESSITY is well-tolerated with few adverse effects. However, patients must continue to manage their glucocorticoid doses to avoid complications.
Read more →NBIXNeurocrine Biosciences to Participate at Investor Conferences in December Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in December. Chief Executive Officer Kyle Gano,...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) is set to participate in two investor conferences in December, specifically the Evercore HealthCONx Conference and Citi's Global Healthcare Conference. CEO Kyle Gano, CFO Matt Abernethy, and Vice-President of Investor Relations Todd Tushla will present during these events. The presentations will be accessible via live webcast on the company's website and will be recorded for later access.
Read more →NBIXNeurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented subgroup analyses and data from the KINECT®-HD study showing the impact of INGREZZA®...
Neurocrine Biosciences has presented new data from the KINECT-HD study demonstrating the efficacy of INGREZZA (valbenazine) in patients with chorea associated with Huntington's disease. The subgroup analysis revealed that INGREZZA consistently reduced chorea across 19 demographics, with significant improvements compared to placebo. Additionally, the study noted enhancements in emotional health without a worsening of psychiatric symptoms, showcasing the treatment's potential broader benefits. The findings will be shared at the upcoming 2024 Annual Meeting of the Huntington Study Group.
Read more →NBIXNeurocrine Biosciences to Participate at Investor Conferences in November Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming investor conferences in November. Chief Executive Officer Kyle Gano,...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) is set to participate in three investor conferences throughout November 2024, including the UBS Global Healthcare Conference and the Stifel Healthcare Conference. The company's CEO, Kyle Gano, will present at these events, which will be webcasted and archived on their website. Neurocrine is known for its focus on developing treatments for neurological and neuroendocrine disorders, emphasizing its dedication to addressing unmet medical needs in these areas.
Read more →NBIXNeurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with INGREZZA®...
Neurocrine Biosciences, Inc. presented promising data at the 2024 Psych Congress regarding the impact of INGREZZA (valbenazine) on patients with tardive dyskinesia. An analysis of over 300 patients indicated significant improvements in various quality of life measures, including functional, social, and emotional aspects. The studies showcased how treatment adherence and overall patient well-being are enhanced with INGREZZA. Additionally, real-world data highlighted a high percentage of patients experiencing improvements, regardless of the severity of their condition.
Read more →NBIXNeurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the long-term KINECT®-4 study demonstrating tardive dyskinesia remission in nearly...
Neurocrine Biosciences reported promising results from the KINECT-4 study on INGREZZA (valbenazine) at the 2024 Psych Congress. Almost 60% of long-term study participants achieved remission of tardive dyskinesia after 48 weeks of treatment. The findings demonstrate clinically meaningful improvements and bolster the evidence for INGREZZA's effectiveness in managing this challenging disorder. Although the treatment was well tolerated overall, some participants experienced minor adverse effects, including urinary tract infections and headaches.
Read more →NBIX▲ +7%on this newsshared move
Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2024 and provided an...
Neurocrine Biosciences announced its financial results for Q3 2024, highlighting significant growth in INGREZZA sales, which reached $616.6 million. The company raised its full-year sales guidance for INGREZZA and authorized a $300 million share repurchase plan, indicating confidence in its future performance. Leadership emphasized the expansion of sales teams for INGREZZA and the anticipated launch of crinecerfont, reinforcing its commitment to enhancing patient care across its therapeutic areas.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and...
Neurocrine Biosciences, Inc. has announced a scheduled conference call and webcast for discussing its third quarter 2024 financial results. This event is set for October 30, 2024, at 5:00 a.m. PT. A press release will precede the call, and a replay will be made available shortly after the event.
Read more →NBIXNeurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study of INGREZZA® (valbenazine)...
Neurocrine Biosciences announced promising interim results from its KINECT-HD2 study, showing that INGREZZA (valbenazine) significantly improves chorea in Huntington's disease patients over 104 weeks. The results indicate sustained improvements regardless of concurrent antipsychotic medication use. These findings emphasize the drug's long-term safety and efficacy in managing chorea, an often debilitating symptom of the disorder. The data will be presented at the 2024 MDS International Congress of Parkinson's Disease and Movement Disorders.
Read more →NBIXNeurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a....
Neurocrine Biosciences, Inc. will participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit on September 26, 2024. Key executives, including CEO-elect Kyle Gano, will present at the event. The live presentation will be available on the company's website, with a replay accessible shortly after the event. Neurocrine focuses on developing treatments for neurological and neuropsychiatric disorders, boasting a diverse portfolio and an active pipeline.
Read more →NBIXNeurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its ERUDITE™ Phase 2 clinical study of investigational compound luvadaxistat...
Neurocrine Biosciences announced that its ERUDITE Phase 2 study of luvadaxistat did not meet its primary endpoint for treating cognitive impairment in schizophrenia. The study failed to replicate significant cognitive improvements seen in a previous trial, the INTERACT study, attributed to high variability in cognitive measures and imbalances among subjects. As a result, Neurocrine will cease development of luvadaxistat and refocus efforts on advancing other compounds for mental health conditions.
Read more →NBIXNeurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the 2024 Cantor Global Healthcare Conference in New York at 3:05 p.m. Eastern Time on ...
Neurocrine Biosciences will participate in the 2024 Cantor Global Healthcare Conference in New York on September 17, 2024. Key executives, including CEO-elect Kyle Gano, will present and engage with attendees. The live presentation will be available via webcast on the company's website, with a replay offered afterward. This involvement underscores Neurocrine's commitment to addressing needs in neuroscience-related treatments.
Read more →NBIX▼ -18.9%on this news
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in...
Neurocrine Biosciences announced positive Phase 2 results for NBI-1117568 in adults with schizophrenia. The once-daily 20 mg dose met its primary endpoint, showing a significant 7.5-point improvement in PANSS scores compared to placebo. The drug was well tolerated, with minimal adverse effects, paving the way for Phase 3 trials expected in early 2025.
Read more →NBIX▼ -18.9%on this news
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p 0.0
Neurocrine Biosciences announced positive Phase 2 results for NBI-1117568, a novel muscarinic M4 agonist aimed at treating schizophrenia. The 20 mg once-daily dose showed a statistically significant 7.5-point improvement in the PANSS total score compared to placebo, with notable reductions in both positive and negative symptoms. Safety data indicated NBI-1117568 was generally well tolerated, with adverse events comparable to placebo. The company plans to advance the drug into Phase 3 trials in early 2025.
Read more →NBIX▼ -18.9%on this news
Neurocrine Biosciences to Participate at Investor Conferences in September Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at two upcoming investor conferences in September. Chief Executive Officer Kevin Gorman,...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate in two investor conferences in September 2024, specifically at the Morgan Stanley 22nd Annual Global Healthcare Conference and the 2024 Wells Fargo Healthcare Conference. These live presentations will be webcast and accessible on the company's website. Neurocrine is dedicated to developing treatments for neurological and neuroendocrine disorders, supported by a strong portfolio and pipeline of FDA-approved and investigational therapies.
Read more →NBIXNeurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Canaccord Genuity 44th Annual Growth Conference in Boston at 3:30 p.m. Eastern Time...
Neurocrine Biosciences, Inc. will present at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 14, 2024. Key executives will discuss the company's strategies and developments in front of investors. The event will be accessible through a live webcast, with a replay available on the company's website afterward. Neurocrine continues to lead in the biopharmaceutical field, focusing on developing treatments for neurological and neuropsychiatric disorders.
Read more →NBIX▲ +8.2%on this news
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2024 and provided an update...
Neurocrine Biosciences, Inc. reported strong financial results for the second quarter of 2024, with net product sales for INGREZZA reaching $580 million, marking a 32% increase year-over-year. The company has raised its sales guidance for INGREZZA to between $2.25 and $2.3 billion for 2024. Additionally, it anticipates key Phase 2 data readouts for two compounds in its pipeline in the third quarter. Kevin Gorman, the company's CEO, expressed confidence in Neurocrine's future as he approaches retirement.
Read more →NBIXNeurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1...
Neurocrine Biosciences has launched a sprinkle formulation of INGREZZA (valbenazine) capsules, specifically designed for patients with tardive dyskinesia and Huntington's disease who have difficulty swallowing. This new formulation allows the medication to be administered easily by sprinkling the contents on soft foods. Approved by the FDA, the INGREZZA SPRINKLE retains the same dosing options as its capsule counterpart and aims to enhance treatment accessibility. While it simplifies administration, the medication is associated with serious side effects, notably in patients with Huntington's disease.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2024 financial results conference call and...
Neurocrine Biosciences, Inc. has scheduled a conference call and webcast to discuss its second quarter 2024 financial results, set for August 1, 2024. The press release is scheduled to be available at 4:00 a.m. PT, followed by the call at 5:00 a.m. PT. Interested parties can access the webcast via the company's website. Neurocrine focuses on developing treatments for various neurological disorders and has a range of products already on the market.
Read more →NBIXNeurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its two New Drug Applications...
Neurocrine Biosciences announced that the FDA has accepted its New Drug Applications for crinecerfont, a treatment for congenital adrenal hyperplasia (CAH), granting Priority Review status. If approved, crinecerfont will be the first new therapy for CAH in 70 years, indicating its potential importance in addressing high unmet medical needs. The FDA's decision accelerates the review timeline, with the target action dates set for late December 2024. The company also holds Orphan Drug and Breakthrough Therapy designations for crinecerfont, reflecting its potential to significantly improve treatment options for this serious condition.
Read more →NBIXNeurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented information from its neuroendocrinology...
Neurocrine Biosciences, Inc. presented its findings at ENDO 2024 regarding its CAHtalyst Phase 3 trials for crinecerfont, an investigational treatment for congenital adrenal hyperplasia (CAH). The data revealed that 63% of participants achieved a critical reduction in glucocorticoid doses while maintaining androgen control. The CAHtalog registry underlined significant comorbidities in CAH patients, particularly those on high glucocorticoid doses, emphasizing the need for optimized management strategies. Overall, the studies support crinecerfont's potential as a new treatment paradigm for CAH.
Read more →NBIXNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine - CAHtalyst™ Pediatric Study Met Primary and Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling...
Neurocrine Biosciences announced promising results from its CAHtalyst Pediatric Phase 3 study of crinecerfont, an investigational treatment for congenital adrenal hyperplasia (CAH). The study demonstrated that crinecerfont effectively reduced androstenedione levels and enabled a significant portion of participants to achieve physiologic glucocorticoid doses, while maintaining androgen control. Observational data indicated favorable trends in related health measures such as insulin resistance and weight management. The results were published in The New England Journal of Medicine, underlining the potential of crinecerfont as a transformative option in CAH management.
Read more →NBIXNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine - CAHtalyst™ Adult Phase 3 Study Met Primary and Important Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and ...
Neurocrine Biosciences announced the publication of positive results from its CAHtalyst Phase 3 study of crinecerfont for treating congenital adrenal hyperplasia (CAH). The study met primary and key secondary endpoints, showing significant glucocorticoid dose reduction while maintaining androstenedione control. Crinecerfont was well tolerated, suggesting it may offer a new treatment approach for CAH patients.
Read more →NBIXNeurocrine Biosciences to Participate at Investor Conferences in June Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in June. Kevin Gorman, Chief Executive Officer,...
Neurocrine Biosciences, Inc. will participate in two upcoming investor conferences in June, namely the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Kevin Gorman will present at both events, which will be webcast live on the company's website. The webcasts will be available for replay shortly after the events and archived for about a month. Neurocrine is focused on developing treatments for unmet needs in neurological disorders.
Read more →NBIXNeurocrine Biosciences Announces CEO Succession Plan Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on...
Neurocrine Biosciences announced that Kevin Gorman, Ph.D., will retire as CEO effective October 11, 2024, with Kyle Gano, Ph.D., appointed as CEO-elect. Gorman founded the company and has led it for over three decades, transitioning Neurocrine into a well-established biopharmaceutical firm with a diverse pipeline. Gano, who has been with Neurocrine for over 23 years, aims to continue advancing their mission to develop treatments for under-addressed neurological disorders. The leadership change is seen as a pivotal moment for the company's future, particularly with upcoming FDA applications for new therapies.
Read more →NBIXNeurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including new...
Neurocrine Biosciences, Inc. has announced its upcoming presentation of crucial Phase 3 clinical study data at the ENDO 2024 conference in Boston. The data will cover the efficacy and safety of crinecerfont, aimed at treating congenital adrenal hyperplasia (CAH), as well as insights from modified-release hydrocortisone studies. This presentation includes findings that may support two New Drug Applications submitted to the FDA. The conference is scheduled from June 1 to June 4, 2024.
Read more →NBIXNeurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of...
Neurocrine Biosciences, Inc. announced the publication of a post hoc analysis from the Phase 3 KINECT-4 study of INGREZZA (valbenazine) for tardive dyskinesia. The analysis indicated that nearly all 103 participants showed clinically meaningful improvements in TD symptoms at the 48-week mark. The findings suggest that INGREZZA is effective for longer-term management of tardive dyskinesia, with participants experiencing tolerable side effects like urinary tract infections and headaches. This reinforces the treatment's potential as a reliable option in real-world clinical settings.
Read more →NBIXNeurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 - CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults - Phase 2...
Neurocrine Biosciences presented new data from its CAHtalyst program at ECE 2024, highlighting the baseline characteristics of patients with congenital adrenal hyperplasia (CAH). The Phase 2 study for modified-release hydrocortisone showed that participants achieved physiological morning cortisol levels after four weeks of treatment. The Phase 3 studies suggested that there are significant treatment challenges, as many subjects presented with comorbidities and elevated hormone levels despite high glucocorticoid doses. This reinforces the need for innovative treatment options for CAH patients across all age groups.
Read more →NBIXNeurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline characteristics for ...
Neurocrine Biosciences announced the presentation of baseline characteristics from the CAHtalyst™ Adult Phase 3 study for congenital adrenal hyperplasia patients at the AACE 2024 Annual Meeting. The findings reveal concerning long-term effects of current treatments, including increased risks of psychiatric disorders and cognitive impairments. Additionally, despite supraphysiologic glucocorticoid doses, patients had elevated hormone levels, highlighting the limitations of existing therapies. The data may inform future treatment approaches with investigational therapies like crinecerfont, aimed at minimizing the side effects of current glucocorticoid treatments.
Read more →NBIXNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety,...
Neurocrine Biosciences, Inc. has announced the initiation of a Phase 1 first-in-human clinical study for its investigational compound NBI-1076986. This oral M4 subtype-selective muscarinic acetylcholine receptor antagonist aims to evaluate safety and pharmacodynamics in healthy adults. The compound is developed for the potential treatment of movement disorders, particularly targeting conditions such as Parkinson's disease tremor and dystonia. Neurocrine's portfolio emphasizes innovative treatments addressing unmet needs in neurological disorders.
Read more →NBIXNeurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced plans to present findings from its neuroendocrinology pipeline at ECE 2024, focusing on data from the CAHtalyst™ program of crinecerfont in treating congenital adrenal hyperplasia (CAH). The company will also share insights on modified-release hydrocortisone aimed at primary adrenal insufficiency. These presentations highlight the potential benefits of decreased adrenal androgen levels and improved treatment regimens that align with the body's natural rhythms. Despite some challenges related to glucocorticoid treatment, the ongoing development showcases Neurocrine's commitment to advancing therapeutic options in this space.
Read more →NBIXNeurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m....
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference on May 14, 2024, at 11:20 a.m. Pacific Time. The presentation will feature CEO Kevin Gorman, CFO Matt Abernethy, and Chief Business Development Officer Kyle Gano. Attendees can access the live webcast on Neurocrine's website, with a replay available shortly after the event.
Read more →NBIXNeurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD during...
Neurocrine Biosciences has reaffirmed its commitment to Tardive Dyskinesia (TD) advocacy during TD Awareness Week, which runs from May 5-11. The initiative aims to enhance awareness, reduce stigma, and improve routine screenings and treatments for individuals affected by TD, a movement disorder resulting from antipsychotic medications. Neurocrine collaborates with various stakeholders to emphasize the need for regular monitoring and proactive care for those at risk. The company also supports the use of measurement-based care to improve treatment outcomes for patients with serious mental illnesses associated with TD.
Read more →NBIXNeurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024 Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for...
Neurocrine Biosciences presented new data at the PES 2024 Annual Meeting regarding the CAHtalyst Pediatric Phase 3 study and CAHtalog Registry. The study revealed baseline characteristics of 103 pediatric CAH patients, highlighting significant treatment management challenges and comorbidities associated with current glucocorticoid therapies. The company also showcased positive top-line results from recent studies on crinecerfont, an investigational drug that may offer a novel approach to managing congenital adrenal hyperplasia effectively. This presentation underscores the need for improved treatment strategies in this rare condition.
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2024 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2024 and provided an update...
Neurocrine Biosciences, Inc. reported its financial results for Q1 2024, showcasing a 23% increase in net product sales for INGREZZA, which totaled $506 million. The company also announced the FDA approval of the INGREZZA Sprinkle formulation and the submission of New Drug Applications for crinecerfont. Additionally, encouraging Phase 2 data for NBI-1065845, aimed at treating Major Depressive Disorder, was revealed, reinforcing the company’s strong pipeline and positioning in neuroscience. Overall, Neurocrine reaffirmed its 2024 sales guidance while continuing to invest in research and development activities.
Read more →NBIXNeurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine)...
Neurocrine Biosciences has received FDA approval for INGREZZA SPRINKLE, a new oral granule formulation of valbenazine, intended for adults with tardive dyskinesia and chorea associated with Huntington's disease. This formulation offers an easier administration option for patients who have difficulty swallowing. It preserves the dosing schedule of one capsule daily while ensuring the same dosage strengths as the original capsules. However, the use of this treatment carries potential serious side effects, particularly concerning mood changes in those with Huntington's disease.
Read more →NBIXNeurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap in the ...
Neurocrine Biosciences has launched an educational initiative called 'WHAT THE C@H?!' aimed at supporting the congenital adrenal hyperplasia (CAH) community. The initiative seeks to provide useful information and a platform for sharing experiences among patients, caregivers, and healthcare providers. Through community insights, the program addresses the challenges of managing CAH, which is a rare genetic condition impacting adrenal hormone production. This effort reflects Neurocrine's commitment to enhancing understanding and treatment of CAH.
Read more →NBIXNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind,...
Neurocrine Biosciences announced positive topline results from its Phase 2 SAVITRI study for NBI-1065845, an investigational treatment for major depressive disorder. The study showed significant improvements in depression scores, and the treatment was well tolerated by participants. With plans to discuss a path to Phase 3 studies with the FDA, NBI-1065845 may offer new hope for patients unresponsive to current treatments. This development highlights the growing focus on innovative therapies for depression, a significant mental health challenge.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced a conference call and webcast to discuss its first quarter 2024 financial results, scheduled for May 1, 2024, at 5:00 a.m. PT. The press release will be made available at 4:00 a.m. PT that same day, and the live webcast can be accessed on the company's website. Following the event, a replay will be available for approximately one month.
Read more →NBIXNeurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the ...
Neurocrine Biosciences announced the first patient has been dosed in its Phase 2 clinical study for NBI-1070770, a novel treatment for major depressive disorder. This double-blind study aims to assess the efficacy, safety, and tolerability of NBI-1070770 compared to placebo. The investigational compound selectively modulates the NMDA NR2B receptor, which is hoped to benefit patients suffering from moderate to severe depression. Approximately 72 adults will be enrolled in the study, conducted at multiple centers across the United States.
Read more →NBIXNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability,...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has commenced a Phase 1 clinical study of NBI-1065890, a second-generation VMAT2 inhibitor, aimed at evaluating its safety and tolerability in healthy adults. This investigational compound represents an opportunity for treating various neurological and neuropsychiatric conditions. The study is indicative of Neurocrine's ongoing commitment to advancing its pipeline and utilizing its expertise in VMAT2 inhibition, which has previously led to the successful approval of valbenazine. The company hopes this new treatment could provide differentiated benefits in clinical settings.
Read more →NBIXNeurocrine Biosciences to Participate at Virtual Investor Conferences in March Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming virtual investor conferences in March. Eiry Roberts, Chief Medical...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced its participation in two virtual investor conferences scheduled for March, specifically the UBS Virtual CNS Day on March 18 and Stifel 2024 Virtual CNS Days Conference on March 19. Live presentations will be available via webcast on the company's website, with replays accessible shortly after. The company's commitment to developing treatments for neurological and neuropsychiatric disorders continues to position it as a leader in the biopharmaceutical field.
Read more →NBIXNeurocrine Biosciences to Participate at Investor Conferences in March Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming investor conferences in March. Matt Abernethy, Chief Financial...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced its participation in three investor conferences scheduled for March 2024. These conferences include the TD Cowen 44th Annual Healthcare Conference, the Leerink Partners Global Biopharma Conference, and the Barclays 26th Annual Global Healthcare Conference. Presentations will be webcast and available for replay on the company's website, ensuring accessibility for interested stakeholders. Neurocrine is focused on developing treatments in the fields of neuroscience, neuroendocrine, and neuropsychiatric disorders.
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full year ended December 31, 2023 and...
Neurocrine Biosciences, Inc. reported strong financial results for the fourth quarter and full year 2023, highlighting significant growth in its flagship product INGREZZA with net sales of $1.84 billion. The company anticipates net product sales of INGREZZA will reach between $2.1 billion and $2.2 billion in 2024. Furthermore, Neurocrine expects to submit a regulatory application for crinecerfont to the FDA in the second quarter of 2024, representing a new treatment option for congenital adrenal hyperplasia. Despite rising expenses in R&D and SG&A, the overall trajectory indicates a robust growth strategy.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference...
Neurocrine Biosciences, Inc. has announced a conference call and webcast for its fourth quarter and year-end 2023 financial results, scheduled for February 7, 2024. The event will begin at 5:00 a.m. PT and will be available for public access via their website. The company is known for its focus on neuro-related biopharmaceuticals and seeks to provide relief for patients with challenging conditions.
Read more →NBIXNeurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Tuesday...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced it will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. CEO Kevin Gorman will deliver the presentation at 9:45 a.m. Pacific Time in San Francisco. The event will be webcast live, with a replay available on the company's website shortly after the event conclusion. Neurocrine is known for its focus on developing treatments for various neurological and neuropsychiatric disorders.
Read more →NBIXNeurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it received Breakthrough Therapy designation from the U.S. Food and Drug Administration...
Neurocrine Biosciences has announced that it received Breakthrough Therapy designation from the U.S. FDA for its investigational drug crinecerfont, aimed at treating congenital adrenal hyperplasia (CAH). This designation acknowledges the serious nature of CAH and the unmet need for improved treatment options. The safety and efficacy results from the Phase 3 CAHtalyst studies suggest that crinecerfont could represent a substantial improvement over current therapies. The company is positioned to further advance its R&D efforts with multiple new clinical candidates expected in the pipeline.
Read more →NBIXNeurocrine Biosciences to Host Analyst Day on December 5, 2023 Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, will hold its Analyst Day focused on its R&D...
Neurocrine Biosciences, Inc. will hold its Analyst Day on December 5, 2023, in New York, focusing on its R&D portfolio and strategic initiatives. The event will feature key management members, including the CEO and Chief Scientific Officer, discussing significant topics like congenital adrenal hyperplasia. It will be open to in-person attendees and available via live webcast, with a replay accessible afterward.
Read more →NBIXNeurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that is has resolved all...
Neurocrine Biosciences has announced the settlement of patent litigation concerning the Abbreviated New Drug Applications for generic versions of INGREZZA. As a result of the settlement, four companies will be able to market generic forms of the drug beginning March 1, 2038, or earlier under certain conditions. This settlement highlights the strength of Neurocrine’s patent portfolio and offers clarity regarding its market exclusivity. The company remains committed to developing treatments for diseases that lack adequate options.
Read more →NBIXNeurocrine Biosciences Provides Development Pipeline Update Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced Phase 2 study results from two ...
Neurocrine Biosciences announced disappointing results from two Phase 2 trials, one involving NBI-921352 for focal onset seizures and another for NBI-1065846 in major depressive disorder. Both drugs failed to demonstrate efficacy, with no meaningful reduction in seizure frequency and primary endpoints not being met. Consequently, the company has decided not to pursue further development of either investigational drug. Despite the setbacks, Neurocrine remains committed to addressing serious neurological and neuropsychiatric disorders.
Read more →NBIXNeurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the availability of DISCOVER TD™, an interactive digital tool designed to help healthcare ...
Neurocrine Biosciences has launched DISCOVER TD™, an interactive digital tool aimed at enhancing healthcare providers’ ability to identify and diagnose tardive dyskinesia. Collaborating with clinical experts and Level Ex, the tool simulates patient interactions using realistic avatars and histories. It encourages experiential learning through gameplay, helping maintain awareness of the disorder's symptoms. The tool was recently awarded the PM360 Trailblazer Award 2023 Gold Winner and is available for use by healthcare providers and students alike.
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies London Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies London Healthcare Conference on Tuesday November 14, 2023 at 3:00 p.m....
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) is scheduled to present at the Jefferies London Healthcare Conference on November 14, 2023. The presentation will be led by CEO Kevin Gorman and other management members, highlighting the company's commitment to neuroscience and treatment advancements. Attendees can access the presentation via a live webcast on the company's website. Following the event, a replay will be available online for approximately one month.
Read more →NBIXNeurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA®...
Neurocrine Biosciences announced interim results from the KINECT-HD2 study showing that INGREZZA (valbenazine) capsules resulted in significant and sustained improvements in chorea symptoms associated with Huntington's disease. These findings were presented at the Huntington Study Group's annual meeting, highlighting improved ratings from both patients and investigators over a 50-week period. The study also monitored treatment-emergent adverse events, which were consistent with previous studies, indicating the drug's safety profile requires careful consideration.
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2023, raised 2023 net...
Neurocrine Biosciences reported strong financial results for Q3 2023, with net product sales of INGREZZA reaching $486 million, reflecting a 29% year-over-year growth. The company raised its sales guidance for INGREZZA to between $1.82 billion and $1.84 billion for the fiscal year 2023. Additionally, studies on Crinecerfont showed positive results in treating congenital adrenal hyperplasia. Neurocrine's Analyst Day is scheduled for December 5, 2023, which will focus on their research and development strategies.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2023 financial results conference call and...
Neurocrine Biosciences, Inc. has announced a conference call and webcast to discuss its financial results for the third quarter of 2023. The call is scheduled for October 31, 2023, starting at 5:00 a.m. Pacific Time, following a press release at 4:00 a.m. PT. This announcement reflects the company's commitment to investor engagement and transparent communication regarding its financial performance. Neurocrine continues to focus on developing treatments for various neurological and psychiatric disorders, showcasing its dedication to addressing significant medical needs.
Read more →NBIXNeurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints CAHtalyst™ Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children ...
Neurocrine Biosciences announced positive results from the Phase 3 CAHtalyst Pediatric Study, showing that crinecerfont significantly reduced serum androstenedione levels in children with congenital adrenal hyperplasia. The study also indicated a decrease in daily glucocorticoid doses while maintaining androgen control. Crinecerfont was well-tolerated, with a high completion rate among participants.
Read more →NBIXNeurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints CAHtalyst Pediatric
Neurocrine Biosciences announced positive results from the Phase 3 CAHtalyst Pediatric Study for crinecerfont, an investigational treatment for congenital adrenal hyperplasia (CAH). The study met its primary endpoint with a significant decrease in serum androstenedione levels and also saw a reduction in daily glucocorticoid doses while maintaining androgen control. Crinecerfont was well-tolerated among participants. The results indicate the potential for crinecerfont to change the treatment landscape for CAH in both pediatric and adult populations.
Read more →NBIXNeurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023 Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the investigational drug ...
Neurocrine Biosciences announced a new post hoc analysis of Phase 2 data of its investigational drug, crinecerfont, aimed at treating classic congenital adrenal hyperplasia (CAH). The analysis indicates that adolescent patients with elevated baseline hormone levels may experience greater treatment responses and androgen level reductions. The study found no serious safety concerns associated with crinecerfont usage. These findings will be presented at the upcoming European Society for Pediatric Endocrinology meeting, with plans for a Phase 3 study data announcement in early Q4 2023.
Read more →NBIXNeurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA)...
Neurocrine Biosciences has announced the acceptance of its New Drug Application by the FDA for INGREZZA oral granules, a new sprinkle formulation of the existing capsule. This formulation aims to address challenges faced by patients with tardive dyskinesia or Huntington's disease who have difficulty swallowing capsules. The FDA has set a PDUFA target action date for the new product on April 30, 2024, enhancing treatment options for these patients.
Read more →NBIX▲ +6.8%on this newsshared move
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data from the Phase 3 CAHtalyst™ Adult Study evaluating the efficacy,...
Neurocrine Biosciences announced positive top-line results from the Phase 3 CAHtalyst study of crinecerfont for adults with congenital adrenal hyperplasia (CAH). The study met its primary endpoint, showing a significant reduction in daily glucocorticoid doses while maintaining androgen control. The treatment was generally well-tolerated, with few serious adverse events reported. The company plans to submit regulatory filings in 2024 based on these results.
Read more →NBIX▲ +6.8%on this newsshared move
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) CAHtalyst Met Primary Endpoint Demonstrating a Statistically
Neurocrine Biosciences announced promising results from the Phase 3 CAHtalyst study of crinecerfont for adults with congenital adrenal hyperplasia (CAH). The study demonstrated a statistically significant reduction in daily glucocorticoid doses and effective androgen control. Key secondary endpoints were also met, indicating crinecerfont's promise as a first-in-class non-glucocorticoid treatment option. The results pave the way for potential regulatory submissions to the FDA and European Medicines Agency in 2024.
Read more →NBIXNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety,...
Neurocrine Biosciences has initiated a Phase 1 first-in-human clinical study to evaluate the safety and effects of NBI-1117570 in healthy adults. This investigational oral compound is a selective dual agonist targeting muscarinic M1 and M4 receptors, which may address both neurological and neuropsychiatric conditions. The study represents a significant step forward for Neurocrine, highlighting potential treatment options for psychosis and cognitive impairment.
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Investor Conferences in September Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in September. Kyle Gano, Chief Business Development ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate in two investor conferences in September. Kyle Gano and Todd Tushla will present at the Wells Fargo Healthcare Conference on September 7, while Kevin Gorman and Matt Abernethy will present at the Morgan Stanley Global Healthcare Conference on September 12. The presentations will be webcast, and replays will be available on the company's website. Neurocrine focuses on developing treatments for neurological and related disorders.
Read more →NBIXNeurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA® (valbenazine) Capsules Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented findings from a data analysis of KINECT®-4 demonstrating a comparable pattern of...
Neurocrine Biosciences reported positive results from their KINECT-4 analysis, which evaluated the effects of INGREZZA in patients with tardive dyskinesia during a 48-week study. The data indicated that both clinician-rated severity and patient-reported impact improved significantly over time. Additionally, the study underscored the importance of using both clinician and patient assessments to gain a holistic view of treatment outcomes. Despite some mild side effects reported, INGREZZA was well-tolerated among the participants.
Read more →NBIXNeurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults ...
Neurocrine Biosciences, Inc. announced new data on its FDA-approved INGREZZA® (valbenazine) capsules, demonstrating early and sustained improvements in chorea associated with Huntington's Disease. The Phase 3 KINECT-HD study showed significant chorea reduction compared to placebo, with benefits observed as early as two weeks into treatment. These findings were presented at the 2023 MDS International Congress and bolster the case for INGREZZA's efficacy in improving quality of life for patients with Huntington's disease. The company continues to explore data to deepen understanding of the treatment's impact.
Read more →NBIXNeurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules ...
Neurocrine Biosciences announced that the FDA has approved INGREZZA (valbenazine) capsules for treating adults with chorea associated with Huntington's disease. Clinical studies, including the Phase 3 KINECT-HD trial, demonstrated that INGREZZA significantly improves chorea severity compared to placebo. INGREZZA offers a straightforward treatment regimen, with one capsule taken once daily. However, the approval comes with safety warnings regarding serious risks such as depression and suicidal ideation in some patients.
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2023 and raised net sales...
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported strong financial results for the second quarter of 2023, highlighting a 26% year-over-year increase in net product sales for INGREZZA, totaling $446.3 million. The company has raised its sales guidance for INGREZZA to between $1.77 billion and $1.82 billion for the year. CEO Kevin Gorman noted the operational readiness for the second half of 2023, emphasizing upcoming pipeline milestones, including a PDUFA date for valbenazine for Huntington's disease. This positive performance includes a substantial increase in both GAAP and non-GAAP net income compared to the same period last year.
Read more →NBIXNeurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it appointed Christine A. Poon, a business leader with extensive experience in the...
Neurocrine Biosciences has announced the appointment of Christine A. Poon to its Board of Directors. Poon, who has significant experience in various leadership roles within the pharmaceutical industry, is expected to contribute valuable insights to the company. She previously held positions at Johnson & Johnson and Bristol-Myers Squibb and has been recognized for her accomplishments in the field. This strategic addition to the board aligns with Neurocrine's commitment to advancing treatments in neuroscience and related fields.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2023 financial results conference call and...
Neurocrine Biosciences, Inc. has announced a conference call and webcast for its second quarter 2023 financial results, set for August 1, 2023. The press release detailing the financial results will be made available an hour prior to the conference call at 4:00 a.m. PT. The call will highlight the company's performance and strategic directions, with a focus on its neuroscience-oriented biopharmaceutical developments. A replay of the webcast will be accessible on the company's website for approximately one month.
Read more →NBIXDiurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023 Diurnal Ltd., a Neurocrine Biosciences company (Nasdaq: NBIX), today announced that it will present new post hoc analyses of Phase 3 extension study...
Diurnal Ltd., a Neurocrine Biosciences company, presented new post hoc analyses from a Phase 3 extension study of modified-release hydrocortisone for patients with congenital adrenal hyperplasia (CAH) at ENDO 2023. The analyses revealed that patients significantly reduced their daily hydrocortisone dose while achieving effective control of androgen levels. After 24 months of treatment, a notable increase in the number of patients maintaining lower levels of 17-hydroxyprogesterone was observed. This data reinforces the potential of modified-release hydrocortisone as a viable treatment option for adults with CAH.
Read more →NBIXNeurocrine Biosciences to Present at the Goldman Sachs 44th Annual Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Thursday, June 15, 2023 at...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 15, 2023. The presentation will feature CEO Kevin Gorman and CFO Matt Abernethy, highlighting the company's neuroscience-focused initiatives. Attendees can access the live webcast through the company's website, which will also provide a recording afterward. Neurocrine is known for its commitment to develop treatments for neurological and neuroendocrine disorders.
Read more →NBIXNeurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented findings from a meta-analysis of three long-term studies evaluating INGREZZA®...
Neurocrine Biosciences has presented new findings on its drug INGREZZA (valbenazine) at the 2023 Psych Congress Elevate, demonstrating its effectiveness in improving tardive dyskinesia (TD) in adults, regardless of their antipsychotic use. The analysis included data from three long-term studies showing significant and sustained improvements in TD symptoms. Despite the efficacy, symptoms may recur after treatment withdrawal, indicating a need for ongoing management in these patients. Overall, the results highlight the lasting impact of INGREZZA for TD treatment and its good tolerability among users.
Read more →NBIXNeurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology - Statistically Significant Improvement in Chorea Associated with Huntington's Disease Seen as Early as Week 2 - Chorea Improvement Supported by...
Neurocrine Biosciences announced the publication of full results from its Phase 3 KINECT-HD study, demonstrating that valbenazine leads to statistically significant improvement in chorea associated with Huntington's disease. Improvements were noted as early as week 2 and supported by measures of global impression change. The FDA has accepted the supplemental New Drug Application for valbenazine, with a PDUFA target date of August 20, 2023. The study’s results, published in The Lancet Neurology, underscore the drug's potential in addressing a critical need for symptomatic treatment.
Read more →NBIXNeurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society 2023 Annual Congress Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced findings from a post hoc analysis of two long-term studies (KINECT™ 3 and KINECT™ 4) of...
Neurocrine Biosciences presented findings from post hoc analyses of long-term studies on INGREZZA (valbenazine) at the SIRS 2023 Annual Congress. The studies demonstrated significant improvement in tardive dyskinesia (TD) symptoms among patients with schizophrenia or schizoaffective disorder. Over 90% of treated patients reported notable symptom improvement while maintaining psychiatric stability. The treatment was generally well tolerated, though some adverse effects, including somnolence and urinary tract infections, were noted.
Read more →NBIXNeurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023 Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that it will present new...
Neurocrine Biosciences will present new Phase 2 and post hoc analyses of data on crinecerfont, an investigational drug for classic congenital adrenal hyperplasia (CAH), at ECE 2023. The data indicate that crinecerfont is associated with significant reductions in key hormone levels in adults with 21-hydroxylase deficiency. Additionally, EFMODY, which is already approved in Europe, has shown positive results in hormone regulation and patient tolerability. Neurocrine is also set to announce Phase 3 study data for crinecerfont in late 2023.
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2023 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2023 and provided an update...
Neurocrine Biosciences, Inc. reported its financial results for Q1 2023, highlighting net product sales of $415.3 million, primarily driven by INGREZZA. The company reiterated its sales guidance for INGREZZA at $1.67 - $1.77 billion for the year. Despite strong sales, it faced a GAAP net loss of $76.6 million, mainly due to high operating expenses. Upcoming milestones include a PDUFA date for valbenazine on August 20, 2023, and top-line data for several investigational programs later this year.
Read more →NBIXNeurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2023 Healthcare Conference at 10:00 a.m. Pacific Time...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2023 Healthcare Conference on May 9, 2023, with CEO Kevin Gorman and CFO Matt Abernethy scheduled to speak. The live presentation will be webcasted and available for replay on the company's website. Neurocrine is a biopharmaceutical company dedicated to addressing neurological and related disorders with both FDA-approved treatments and an expanding pipeline of clinical developments.
Read more →NBIXNeurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its continued support of increasing awareness regarding the prevalence, impact and...
Neurocrine Biosciences announced support for Tardive Dyskinesia (TD) Awareness Week, aiming to raise awareness about the condition and its effects. This initiative is part of a larger effort to ensure proper diagnosis and treatment for the approximately 600,000 Americans affected by TD. Despite increased awareness since 2018, a significant portion of patients remain undiagnosed. Healthcare providers are encouraged to conduct regular screenings to better assist patients on antipsychotic medications.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2023 financial results conference call and...
Neurocrine Biosciences, Inc. has announced a conference call and webcast scheduled for May 3, 2023, to discuss its first quarter 2023 financial results. The press release will be made public at 4:30 a.m. PT, followed by the conference call at 5:00 a.m. PT. This event reflects the company's commitment to keeping investors informed about its financial performance and strategy moving forward.
Read more →NBIXNeurocrine Biosciences to Present at the Stifel 2023 CNS Days Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2023 CNS Days at 12:30 p.m. Eastern Time on Tuesday, March 28, 2023. Eiry...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) is scheduled to present at the Stifel 2023 CNS Days on March 28, 2023, at 12:30 p.m. Eastern Time. Chief Medical Officer Eiry Roberts and Chief Business Development and Strategy Officer Kyle Gano will represent the company. The presentation will be available as a live webcast and accessible for replay on the company's website shortly after the event.
Read more →NBIXNeurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that new data from RE-KINECT™, the largest real-world, observational, multicenter study...
Neurocrine Biosciences announced the RE-KINECT study results, which evaluated the effects of possible tardive dyskinesia (TD) on patient health and social functioning. It involved a cohort of 1,148 patients from outpatient psychiatry clinics and revealed that awareness of involuntary movements significantly impacts patients' daily lives and wellness. The study emphasizes the need for clinicians to ask about the impact of TD symptoms on patient activities to develop effective treatment plans. Overall, it highlights a gap in comprehensive assessments of the quality of life affected by TD.
Read more →NBIXNeurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from three in vitro dissolution studies exploring the dissolution...
Neurocrine Biosciences announced the presentation of in vitro dissolution studies for INGREZZA (valbenazine) capsule contents at the AMDA - PALTC 2023 Annual Conference. The studies indicated that crushing the capsules did not impact their dissolution performance. This is particularly significant for elderly patients with tardive dyskinesia, who may struggle with swallowing whole capsules. The research aims to improve administration options for this demographic, showcasing the potential versatility of INGREZZA.
Read more →NBIXNeurocrine Biosciences to Participate at Investor Conferences in March Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Kevin Gorman, Chief Executive Officer,...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate in two investor conferences in March 2023. CEO Kevin Gorman and CFO Matt Abernethy will present at the Barclays Global Healthcare Conference on March 15 and the Jefferies Biotech on the Bay Summit on March 16, both in Miami. The presentations aim to enhance investor relations and showcase the company's ongoing development of treatments for neurological disorders.
Read more →NBIXNeurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyzing the long-term outcomes of treating tardive dyskinesia (TD) ...
Neurocrine Biosciences presented data at the AAGP 2023 Annual Meeting regarding the long-term effects of INGREZZA (valbenazine) in treating tardive dyskinesia (TD) among older patients. The studies highlighted significant symptom reductions, with over 80% of patients aged 65 and above achieving more than 50% improvement on the AIMS scale. Additionally, these findings suggest that INGREZZA can maintain psychiatric stability, thus affirming its potential benefits for older adults with TD.
Read more →NBIXNeurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual SVB Securities Global Biopharma Conference at 12:00 p.m. Eastern Time on...
Neurocrine Biosciences, Inc. will present at the SVB Securities Global Biopharma Conference on February 14, 2023, at 12:00 p.m. Eastern Time. The presentation will feature CEO Kevin Gorman and CFO Matt Abernethy and will be available as a live webcast on the company's website. Following the event, a replay will be accessible on their site for about one month. Neurocrine is focused on developing treatments for neurological and neuropsychiatric disorders.
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022 and...
Neurocrine Biosciences reported strong financial results for the fourth quarter and fiscal year 2022, marking significant growth in revenue and net income. The company expects considerable sales from its key product INGREZZA, with guidance set between $1.67 billion and $1.77 billion for 2023. Additionally, the completion of enrollment in registrational studies for crinecerfont positions Neurocrine favorably for upcoming clinical data releases. Despite this success, there were previous losses in Q4 2021 that emphasize ongoing challenges in managing operational expenses.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference...
Neurocrine Biosciences, Inc. announced a conference call and webcast scheduled for February 6, 2023, to discuss its fourth quarter and year-end 2022 financial results. The press release will be available at 4:30 a.m. PT, followed by the call at 5:00 a.m. PT. The event can be accessed via their website, with a replay expected to be archived for one month. The company emphasizes its mission to provide relief for patients with neurological and neuropsychiatric disorders.
Read more →NBIX▼ -12.2%on this news
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager's GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases - Voyager t
Neurocrine Biosciences and Voyager Therapeutics have entered into a strategic collaboration focused on the development and commercialization of gene therapies for neurological diseases. Voyager will receive an upfront payment of $175 million, including a significant equity investment, along with potential milestone payments and royalties. Neurocrine will obtain worldwide rights to Voyager's GBA1 gene therapy program, which targets Parkinson's disease and other related conditions. The collaboration aims to leverage innovative technologies from both companies to advance treatments for serious neurological disorders.
Read more →NBIXNeurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 41st Annual J.P. Morgan Healthcare Conference at 11:15 a.m. Pacific Time on Monday...
Neurocrine Biosciences, Inc. will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. Pacific Time. CEO Kevin Gorman is set to lead the presentation, which will be accessible via live webcast on the company’s website. Neurocrine focuses on developing treatments for various neurological, neuroendocrine, and neuropsychiatric disorders and is known for its established FDA-approved therapies as well as ongoing clinical programs.
Read more →NBIXNeurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that the U.S. Food and Drug...
SAN DIEGO , Dec. 22, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ), a leading neuroscience-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for valbena
Read more →NBIXNeurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that investigational...
SAN DIEGO , Dec. 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ), a leading neuroscience-focused biopharmaceutical company, today announced that investigational NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT™ study evaluating the effica
Read more →NBIXNeurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022 Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported demographic and clinical...
SAN DIEGO , Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ), a leading neuroscience-focused biopharmaceutical company, today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A -related epile
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Healthcare Conferences Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor...
SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that members of the management team will participate at the following investor conferences: The live presentations will be webcast and may be accessed on the Company's website u
Read more →NBIXNeurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from a study on INGREZZA® (valbenazine) capsules evaluating in vitro ...
SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced it will present data from a study on INGREZZA ® (valbenazine) capsules evaluating in vitro dissolution performance of whole intact or crushed capsule contents in 40 mg and 80 mg
Read more →NBIXNeurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022 Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported additional results from the...
SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), a leading neuroscience-focused biopharmaceutical company, today reported additional results from the Phase 3 KINECT-HD study investigating valbenazine for the treatment of chorea associated wit
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2022 and raised net sales ...
INGREZZA ® (valbenazine) Third Quarter Net Product Sales of $376 Million INGREZZA ® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.4 - $1.425 Billion Supplemental New Drug Application (sNDA) of Valbenazine For the Treatment of Chorea in Patients with Huntington Dise
Read more →NBIXNeurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced the first patient has been...
SAN DIEGO , Oct. 27, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ), a leading neuroscience-focused biopharmaceutical company, today announced the first patient has been randomized for its Phase 2 placebo-controlled, inpatient clinical study evaluating the effi
Read more →NBIXNeurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented data detailing the baseline characteristics of patients with Parkinson's disease (PD) in...
SAN DIEGO , Oct. 24, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today presented data detailing the baseline characteristics of patients with Parkinson's disease (PD) in the Opicapone Treatment Initiation Open-Label Study (OPTI-ON). The poster (Poster #M193)
Read more →NBIXNeurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced data on the real-world comorbidities, polypharmacy, and treatment patterns of patients on ...
SAN DIEGO , Oct. 19, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced data on the real-world comorbidities, polypharmacy, and treatment patterns of patients on newly prescribed benztropine who were also being treated with antipsychotic medications
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2022 financial results conference call and...
Conference Call and Webcast Scheduled for Tuesday, November 1 SAN DIEGO , Oct. 11, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it has scheduled its third quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific T
Read more →NBIXNeurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief...
SAN DIEGO , Sept. 29, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1 , leading the regulatory affairs, quality assurance, me
Read more →NBIXNeurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data demonstrating sustained improvements with long-term INGREZZA®...
SAN DIEGO , Sept. 19, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it will present data demonstrating sustained improvements with long-term INGREZZA ® (valbenazine) capsules treatment in adults with tardive dyskinesia (TD) at the Psych Co
Read more →NBIXNeurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstrating the need for education on supportive...
SAN DIEGO , Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced the presentation of survey findings demonstrating the need for education on supportive evidence regarding best approaches to managing tardive dyskinesia (TD) symptoms while mai
Read more →NBIXNeurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today will present data on the effects of ONGENTYS® (opicapone) capsules on...
SAN DIEGO , Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today will present data on the effects of ONGENTYS ® (opicapone) capsules on soluble-catechol-O-methyltransferase (S-COMT) enzyme inhibition. These data (abstract #1025) are being shared at th
Read more →NBIXParkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care Partners Parkinson & Movement Disorder (PMD) Alliance, in partnership with Neurocrine Biosciences (Nasdaq: NBIX), a leading neuroscience-focused...
SAN DIEGO , Sept. 12, 2022 /PRNewswire/ -- Parkinson & Movement Disorder (PMD) Alliance, in partnership with Neurocrine Biosciences (Nasdaq: NBIX ), a leading neuroscience-focused biopharmaceutical company committed to meeting the needs of people with complex and debilitating dis
Read more →NBIXNeurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 10:35 a.m. Eastern Time on ...
SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Morgan Stanley 20 th Annual Global Healthcare Conference at 10:35 a.m. Eastern Time on Tuesday , September 13, 2022 in New York . Kevin Gorman , Chief Executive Officer, and
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2022 and raised net sales...
INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $350 Million INGREZZA ® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.35 - $1.40 Billion Essential Tremor Signal-Seeking Study Did Not Meet Specified Endpoints SAN DIEGO , Aug. 4, 2022 /PRNewswire/ -- Ne
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2022 financial results after the Nasdaq market closes...
Conference Call and Webcast Scheduled for Thursday, August 4 SAN DIEGO , July 14, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. ( Nasdaq : NBIX ) announced today that it will report second quarter 2022 financial results after the Nasdaq market closes on Thursday, August 4, 2
Read more →NBIXNeurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new Phase 2 data on the use of crinecerfont in adolescent patients...
- Substantial Reductions in Key Hormones and Hormone Precursors Observed After 14 Days of Crinecerfont Treatment in Adolescents with Classic CAH - Two Phase 3 Global Registrational Studies Currently Underway in Pediatric (2–17 years of age) and Adult (18 years of age and older)
Read more →NBIXNeurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time...
SAN DIEGO , June 8, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Goldman Sachs 43 rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time ( 1:40 p.m. Eastern Time ) on Wednesday, June 15, 2022 in Rancho Palos Verdes, CA. Kevin Go
Read more →NBIXNeurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala Neurocrine Biosciences, Inc. (Nasdaq: NBIX) was honored by the CARES Foundation for its ongoing research and development of novel therapies for...
SAN DIEGO , June 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) was honored by the CARES Foundation for its ongoing research and development of novel therapies for patients with classic congenital adrenal hyperplasia (CAH). The CARES Foundation, Inc. is the
Read more →NBIXNeurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presents data on sleep disturbances in Parkinson's disease (PD) demonstrating the impact of OFF...
SAN DIEGO , June 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today presents data on sleep disturbances in Parkinson's disease (PD) demonstrating the impact of OFF episodes, or reemergence of symptoms between doses of levodopa, on falling asleep and stayin
Read more →NBIXNeurocrine Biosciences Announces Repurchase of Convertible Notes
Neurocrine Biosciences Announces Repurchase of Convertible Notes SAN DIEGO, May 24, 2022 - Neurocrine Biosciences, Inc. (Nasdaq NBIX) (the "Company" or "Neurocrine Biosciences") today announced that it has entered into separate, privately negotiated transactions (the "Agreements
Read more →NBIXNeurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data on the use of INGREZZA® (valbenazine) capsules for the...
SAN DIEGO , May 23, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it will present data on the use of INGREZZA ® (valbenazine) capsules for the treatment of tardive dyskinesia (TD) at the American Psychiatric Association (APA) Annual Meetin
Read more →NBIXNeurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration...
SAN DIEGO , May 12, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for valbenazine as a treatment for Huntington disease (HD). The treatment of chorea
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance INGREZZA (valbenazine) First Quarter Net Product Sales of $303 Million INGREZZA (valbenazine) 2022 Net Product Sa
Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance INGREZZA (valbenazine) First Quarter Net Product Sales of $303 Million INGREZZA (valbenazine) 2022 Net Product Sales Guidance Reiterated at $1.25 - $1.35 Billion SAN DIE
Read more →NBIXNeurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2022 Healthcare Conference at 11:20 a.m. Pacific Time...
SAN DIEGO , May 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Bank of America Securities 2022 Healthcare Conference at 11:20 a.m. Pacific Time ( 2:20 p.m. Eastern Time ) on Tuesday, May 10, 2022 in Las Vegas . Kevin Gorman , Chief Execut
Read more →NBIXNeurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its support of Mental Health Awareness Month and commitment to raising awareness of and...
SAN DIEGO , May 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced its support of Mental Health Awareness Month and commitment to raising awareness of and supporting people living with tardive dyskinesia (TD) through Tardive Dyskinesia Awareness
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2022 financial results conference call and...
Conference Call and Webcast Scheduled for Wednesday, May 4 SAN DIEGO , April 13, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it has scheduled its first quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Tim
Read more →NBIXNeurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022 - Valbenazine Met the Primary Endpoint of Significant (p 0.0001) Improvement in Chorea Severity versus Placebo as Measured by the Unified...
- Valbenazine Met the Primary Endpoint of Significant ( p <0.0001) Improvement in Chorea Severity versus Placebo as Measured by the Unified Huntington's Disease Rating Scale ( UHDRS ® ) Total Maximal Chorea ( TMC ) Score, with Improvements Beginning in Week 2 - Clinically Meanin
Read more →NBIXNeurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained...
SAN DIEGO , March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of DYSVAL ® capsules 40 mg (valbenazine) for the treatment of tardive
Read more →NBIXNeurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data on treatment patterns and unmet needs in adult and...
SAN DIEGO , March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it will present new data on treatment patterns and unmet needs in adult and pediatric patients with classic congenital adrenal hyperplasia (CAH) at the Academy of Managed
Read more →NBIXNeurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders program and telemedicine research...
SAN DIEGO , March 24, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it will present data from its movement disorders program and telemedicine research at the American Academy of Neurology (AAN) Annual Meeting being held in person April 2–7
Read more →NBIXNeurocrine Biosciences to Present at Stifel 2022 CNS Days Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2022 CNS Days virtual conference at 3:30 p.m. Eastern Time on Monday, March...
SAN DIEGO , March 21, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Stifel 2022 CNS Days virtual conference at 3:30 p.m. Eastern Time on Monday , March 28, 2022. Eiry Roberts, Chief Medical Officer, and Kyle Gano , Chief Business Developmen
Read more →NBIX▲ +7.4%on this news
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022 INGREZZA (valbenazine) 2021 Net Product Sales of $1.1 Billion with 200,000 TRx INGREZZA
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022 INGREZZA (valbenazine) 2021 Net Product Sales of $1.1 Billion with 200,000 TRx INGREZZA (valbenazine) 2022 Net Product Sales Guidance of $1.25 - $
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference...
SAN DIEGO , Jan. 25, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on Friday, Februar
Read more →NBIXNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestone s INGREZZA (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones INGREZZA (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $301 Million and 56,400 Total Prescriptions INGREZZA (valb
Read more →NBIXNeurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual 40th Annual J.P. Morgan Healthcare Conference at 11:15 a.m. Eastern Time on...
SAN DIEGO , Jan. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference at 11:15 a.m. Eastern Time on Monday Jan. 10, 2022. Kevin Gorman , Chief Executive Officer, will present at the confere
Read more →NBIXNeurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease Neurocrine Biosciences (Nasdaq: NBIX) today announced positive top-line data from its Phase 3 KINECT-HD study evaluating the efficacy, safety and...
SAN DIEGO , Dec. 7, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX ) today announced positive top-line data from its Phase 3 KINECT-HD study evaluating the efficacy, safety and tolerability of valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor
Read more →NBIXNeurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Jude Onyia, Ph.D., has joined the company's executive management team as Chief...
SAN DIEGO , Nov. 30, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that Jude Onyia , Ph.D., has joined the company's executive management team as Chief Scientific Officer. Dr. Onyia, a scientist with more than 25 years of experience in the phar
Read more →NBIXNeurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders Neurocrine Biosciences anticipates initiating a Phase
Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizo
Read more →NBIXNeurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it presented new data from its movement disorder program for tardive dyskinesia (TD) ...
SAN DIEGO , Nov. 1, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it presented new data from its movement disorder program for tardive dyskinesia (TD) at the 2021 Psych Congress scientific meeting being held October 29–November 1, 2021. K
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2021 Financial Results INGREZZA (valbenazine) Third Quarter 2021 Net Product Sales of $287 Million with Approximately 52,000 Total Prescriptions
Neurocrine Biosciences Reports Third Quarter 2021 Financial Results INGREZZA (valbenazine) Third Quarter 2021 Net Product Sales of $287 Million with Approximately 52,000 Total Prescriptions SAN DIEGO, Nov. 1, 2021 - Neurocrine Biosciences, Inc. (Nasdaq NBIX) today announced its
Read more →NBIXNeurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its movement disorder treatments for...
SAN DIEGO , Oct. 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it will present key information from its movement disorder treatments for Parkinson's disease and tardive dyskinesia (TD) at the American Neurological Association (ANA) 202
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter 2021 financial results after the Nasdaq market closes...
SAN DIEGO , Oct. 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it will report third quarter 2021 financial results after the Nasdaq market closes on Monday, November 1, 2021 . Neurocrine will then host a conference call and webcast to
Read more →NBIXNeurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a collaboration with renowned contemporary artist, Jorge Rodriguez-Gerada best known for...
SAN DIEGO , Oct. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced a collaboration with renowned contemporary artist, Jorge Rodriguez-Gerada best known for his urban large-scale mural portraits, to create an original piece of art called Monument
Read more →NBIXNeurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congress 2021 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from its movement disorder treatments for tardive...
SAN DIEGO , Sept. 10, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (TD) and Parkinson's disease at the International Parkinson and Movement Disorder Soc
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Healthcare Conferences Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following virtual investor...
SAN DIEGO , Sept. 2, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that members of the management team will participate at the following virtual investor conferences: The live presentation will be webcast and may be accessed on the Company's w
Read more →NBIXNeurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease Neurocrine Biosciences, Inc. (Nasdaq: NBIX), in collaboration with the Huntington Study Group, today announced the completion of patient enrollment...
SAN DIEGO , Aug. 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ), in collaboration with the Huntington Study Group , today announced the completion of patient enrollment for its Phase 3 ( KINECT-HD ) clinical study evaluating the efficacy, safety and tolerabi
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2021 Financial Results INGREZZA (valbenazine) Second Quarter 2021 Net Product Sales of $265 Million with Approximately 48,900 Total Prescriptions Phase 3 Registrational Progr
Neurocrine Biosciences Reports Second Quarter 2021 Financial Results INGREZZA (valbenazine) Second Quarter 2021 Net Product Sales of $265 Million with Approximately 48,900 Total Prescriptions Phase 3 Registrational Program of Valbenazine for the Treatment of Chorea Associated w
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes...
SAN DIEGO , July 19, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesday, August 3, 2021 . Neurocrine will then host a conference call and webcast to
Read more →NBIXNeurocrine Biosciences to Participate at the William Blair Biotech Focus Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Kyle Gano, Chief Business Development and Strategy Officer, will participate in a...
SAN DIEGO , July 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that Kyle Gano , Chief Business Development and Strategy Officer, will participate in a neuropsychology-focused panel discussion at the William Blair Biotech Focus Conference at
Read more →NBIXNeurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on...
SAN DIEGO , June 1, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Goldman Sachs 42 nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday , June 8, 2021. Kevin Gorman , Chief Executive Officer, will present at the confe
Read more →NBIXNeurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday...
SAN DIEGO , May 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 2021. Matt Abernethy , Chief Financial Officer, and Eiry Roberts, Chief Medical O
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2021 Financial Results INGREZZA (valbenazine) First Quarter 2021 Net Product Sales of $230 Million with Approximately 43,300 TRx Initiated Pediatric Phase III Registrational P
Neurocrine Biosciences Reports First Quarter 2021 Financial Results INGREZZA (valbenazine) First Quarter 2021 Net Product Sales of $230 Million with Approximately 43,300 TRx Initiated Pediatric Phase III Registrational Program of Crinecerfont for the Treatment of Classic Congen
Read more →NBIXNeurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday May...
SAN DIEGO , May 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Bank of America 2021 Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday May 11, 2021. Kevin Gorman , Chief Executive Officer, will present at the conference. The liv
Read more →NBIXNeurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its support of Mental Health Month and commitment to raising awareness of and supporting...
SAN DIEGO , May 3, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced its support of Mental Health Month and commitment to raising awareness of and supporting people living with tardive dyskinesia (TD). Some people living with a mental health condit
Read more →NBIXNeurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief...
SAN DIEGO , April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Officer of Gilead Sciences, with responsibility for the global commercializati
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter 2021 financial results after the Nasdaq market closes...
SAN DIEGO , April 14, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it will report first quarter 2021 financial results after the Nasdaq market closes on Wednesday, May 5, 2021 . Neurocrine will then host a conference call and webcast to d
Read more →NBIXNeurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the...
SAN DIEGO , April 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurology's (AAN) 73rd Annual Meeting being held virtually from April 17–2
Read more →NBIXNeurocrine Biosciences to Present at Stifel 3rd Annual CNS Day Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021. Eiry...
SAN DIEGO , March 25, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Stifel 3 rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021. Eiry Roberts, Chief Medical Officer, and Kyle Gano , Chief Business Development and Strategy
Read more →NBIXNeurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present additional positive data from its Phase II CAHlibrate study of...
SAN DIEGO , March 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it will present additional positive data from its Phase II CAHlibrate study of crinecerfont, an investigational, oral, non-steroidal corticotropin-releasing factor type 1
Read more →NBIXNeurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday...
SAN DIEGO , March 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Oppenheimer 31 st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021. Matt Abernethy , Chief Financial Officer, will present at the conference.
Read more →NBIXNeurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS) Neurocrine Biosciences (Nasdaq: NBIX) today announced that investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet its primary endpoint...
SAN DIEGO , March 2, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX ) today announced that investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet its primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as mea
Read more →NBIXNeurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 41st Annual Health Care Conference at 1:30 p.m. Eastern Time on Tuesday Mar. 2, ...
SAN DIEGO , Feb. 23, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Cowen 41 st Annual Health Care Conference at 1:30 p.m. Eastern Time on Tuesday Mar. 2, 2021. Kevin Gorman , Chief Executive Officer, will present at the conference. The liv
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results Total Annual Revenues in 2020 Grew 33% to Over $1 Billion INGREZZA (valbenazine) Full Year 2020 Net Product Sales and TRx Both Grew 32% t
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results Total Annual Revenues in 2020 Grew 33% to Over $1 Billion INGREZZA (valbenazine) Full Year 2020 Net Product Sales and TRx Both Grew 32% to $993 Million and Approximately 175,700 TRx, Respectively
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq...
SAN DIEGO , Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq market closes on Thursday, Feb. 4, 2021 . Neurocrine will then host a conference call and
Read more →NBIXNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestone s INGREZZA (valbenazine) Preliminary Fourth Quarter Net Product Sales and Inventory Adjus
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones INGREZZA (valbenazine) Preliminary Fourth Quarter Net Product Sales and Inventory Adjusted Net Product Sales of Approximately $240 Million and $25
Read more →NBIXNeurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on Monday Jan....
SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the 39 th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on Monday Jan. 11, 2021. Kevin Gorman , Chief Executive Officer, will present at the conference. The
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Healthcare Conferences Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor...
SAN DIEGO , Nov. 19, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that Neurocrine Biosciences management will present at the following investor conferences: The live presentations will be webcast and may be accessed on the Company's website u
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2020 Financial Results INGREZZA (valbenazine) Third Quarter Net Product Sales of $254 million with Approximately 45,100 TRx ONGENTYS (opicapone) Now Available in the U.S. as a
Neurocrine Biosciences Reports Third Quarter 2020 Financial Results INGREZZA (valbenazine) Third Quarter Net Product Sales of $254 million with Approximately 45,100 TRx ONGENTYS (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease E
Read more →NBIXNeurocrine Biosciences and Me2/Orchestra, in Partnership with Mental Health Advocacy Groups, Honor Mental Illness Awareness Week by Launching Monumental Moments™, an Online Community Platform and Charitable Initiative to Support, Inspire and Connect People During the Pandemic Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Boston-based Me2/Orchestra, the world's only known classical music organization created for people...
SAN DIEGO and BOSTON , Oct. 7, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) and Boston -based Me2/Orchestra, the world's only known classical music organization created for people with mental illness and the people that support them, today announced that they
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on...
SAN DIEGO , Oct. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, November 9, 2020 . Neurocrine will then host a conference call and webcast to discus
Read more →NBIXNeurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyses evaluating the efficacy and safety of ONGENTYS® (opicapone) ...
SAN DIEGO , Sept. 28, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced it will present data analyses evaluating the efficacy and safety of ONGENTYS ® (opicapone) capsules, recently approved by the U.S. Food and Drug Administration (FDA) as the fir
Read more →NBIXNeurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing Off Episodes Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that 50 mg capsules of ONGENTYS® (opicapone), the first and only FDA-approved once-daily...
SAN DIEGO , Sept. 14, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that 50 mg capsules of ONGENTYS ® (opicapone), the first and only FDA-approved once-daily catechol-O-methyltransferase (COMT) inhibitor, are now available by prescription in th
Read more →NBIXNeurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from PD-1101, a Phase Ib open-label,...
SAN DIEGO and CAMBRIDGE, Mass. , Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) and Voyager Therapeutics, Inc. (Nasdaq: VYGR ) today announced data from PD-1101, a Phase Ib open-label, three-year efficacy and safety study, demonstrating that a one-tim
Read more →NBIXNeurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from two post-hoc analyses of Phase III data, demonstrating that once-daily...
SAN DIEGO , Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced new data from two post-hoc analyses of Phase III data, demonstrating that once-daily ONGENTYS ® (opicapone) capsules decreased "off" time and increased "on" time without troubl
Read more →NBIXNeurocrine Biosciences at Citi 15 th Annual Biopharma Virtual Conference
Neurocrine Biosciences at Citi 15th Annual Biopharma Virtual Conference September 09, 2020 12 35PM ET Corporate Participant Kevin C. Gorman Neurocrine Biosciences, Inc. - CEO Director Conference Call Participant Neena Bitritto-Garg Citi Investment Research - VP Neena Bitrit
Read more →NBIXNeurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 18th Annual Global Healthcare Conference at 1:30 p.m. ET on Monday,...
SAN DIEGO , Sept. 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Morgan Stanley 18 th Annual Global Healthcare Conference at 1:30 p.m. ET on Monday, September 14, 2020 . Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief F
Read more →NBIXNeurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data as part of 30 abstracts accepted from its movement disorder...
SAN DIEGO , Sept. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced it will present new data as part of 30 abstracts accepted from its movement disorder programs for tardive dyskinesia and Parkinson's disease at the upcoming virtual scientific m
Read more →NBIXNeurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Citi 15th Annual BioPharma Virtual Conference at 12:35 p.m. ET on Wednesday,...
SAN DIEGO , Sept. 2, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Citi 15 th Annual BioPharma Virtual Conference at 12:35 p.m. ET on Wednesday, September 9, 2020 . Kevin Gorman , Chief Executive Officer, will present at the conference. Th
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2020 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2020 and provided revised...
SAN DIEGO , Aug. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced its financial results for the second quarter ended June 30, 2020 and provided revised full-year 2020 financial expense guidance. "I want to thank healthcare providers and our em
Read more →NBIXNeurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the William Blair Biotech Focus Conference 2020 at 12:00 p.m. ET on Thursday, August...
SAN DIEGO , July 30, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will participate at the William Blair Biotech Focus Conference 2020 at 12:00 p.m. ET on Thursday , August 6, 2020. Kyle Gano , Chief Business Development and Strategy Officer, will participate
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on...
SAN DIEGO , July 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it will report second quarter financial results after the Nasdaq market closes on Monday, August 3, 2020 . Neurocrine will then host a conference call and webcast to discus
Read more →NBIXNeurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders Strategic partnership agreement provides Neurocrine Biosciences exclusive worldwide righ
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders SAN DIEGO and Osaka, Japan, June 16, 2020 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TA
Read more →NBIXNeurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2020 Napa Biopharma Conference at 2:00 p.m. PT (5:00 p.m....
SAN DIEGO , June 15, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Bank of America Securities 2020 Napa Biopharma Conference at 2:00 p.m. PT ( 5:00 p.m. ET ) on Monday, June 22, 2020 . Kevin Gorman , Chief Executive Officer, will present at
Read more →NBIXNeurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive data from its completed open-label, multiple-dose, dose-finding, Phase II...
SAN DIEGO , June 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced positive data from its completed open-label, multiple-dose, dose-finding, Phase II clinical study of crinecerfont (NBI-74788), demonstrating meaningful reductions in all three ke
Read more →NBIXNeurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast at 9:40 a.m. ET on...
SAN DIEGO , June 4, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Goldman Sachs 41 st Annual Global Healthcare Conference Webcast at 9:40 a.m. ET on Thursday , June 11, 2020. Kevin Gorman , Chief Executive Officer, Eiry Roberts, Chief Medic
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies Virtual Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, June 2, 2020....
SAN DIEGO , May 26, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Jefferies Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday , June 2, 2020. Kevin Gorman , Chief Executive Officer, will present at the conference. The live presenta
Read more →NBIXNeurocrine Biosciences to Present at the RBC Capital Markets 2020 Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the RBC Capital Markets 2020 Global Healthcare Conference at 3:40 p.m. ET on Tuesday, May ...
SAN DIEGO , May 14, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the RBC Capital Markets 2020 Global Healthcare Conference at 3:40 p.m. ET on Tuesday , May 19, 2020. Kevin Gorman , Chief Executive Officer, will present at the conference. The
Read more →NBIXNeurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that multiple scientific presentations and abstracts from its movement disorder programs...
SAN DIEGO , May 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that multiple scientific presentations and abstracts from its movement disorder programs will be available on the 2020 American Academy of Neurology (AAN) Annual Meeting Science
Read more →NBIXNeurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Idorsia Ltd (SIX: IDIA) today announced, following Investigational New Drug (IND) application...
SAN DIEGO and ALLSCHWIL, Switzerland , May 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) and Idorsia Ltd (SIX: IDIA) today announced, following Investigational New Drug (IND) application acceptance by the U.S. Food and Drug Administration (FDA), Neurocrine
Read more →NBIXNeurocrine Biosciences Announces New Data Published from the Largest Real-World Screening Study, RE-KINECT, Demonstrating that Movements Consistent with Tardive Dyskinesia Occur Frequently and Can Reduce Quality of Life in Patients with Psychiatric Disorders Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new data from RE-KINECT, the largest ever real-world screening study...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the publication of new data from RE-KINECT, the largest ever real-world screening study of patients with clinician-confirmed possible tardive dyskinesia (TD) demonstrating that th
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2020 Financial Results INGREZZA (valbenazine) First Quarter Net Product Sales of $231 Million with Approximately 41,500 TRx ONGENTYS (opicapone) Approved by the U.S. Food and
Neurocrine Biosciences Reports First Quarter 2020 Financial Results INGREZZA (valbenazine) First Quarter Net Product Sales of $231 Million with Approximately 41,500 TRx ONGENTYS (opicapone) Approved by the U.S. Food and Drug Administration (FDA) as a Once-Daily Adjunctive Treat
Read more →NBIXNeurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2020 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2020 at 2:20 p.m. ET on Tuesday, ...
SAN DIEGO , May 5, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Bank of America Merrill Lynch Health Care Conference 2020 at 2:20 p.m. ET on Tuesday , May 12, 2020. Kevin Gorman , Chief Executive Officer, will present at the conference. T
Read more →NBIXNeurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing Off Episodes Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral ONGENTYS®...
SAN DIEGO , April 27, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral ONGENTYS ® (opicapone) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in pa
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter financial results after the Nasdaq market closes on...
SAN DIEGO , April 15, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it will report first quarter financial results after the Nasdaq market closes on Wednesday, May 6, 2020 . Neurocrine will then host a conference call and webcast to discus
Read more →NBIXNeurocrine Biosciences Provides COVID-19 Business Update Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update regarding the company's business operations during the COVID-19 pandemic as part ...
SAN DIEGO , April 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today provided an update regarding the company's business operations during the COVID-19 pandemic as part of its commitment to prioritize the safety, health and well-being of patients, their ca
Read more →NBIXNeurocrine Biosciences to Present at Cowen 40th Annual Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 40th Annual Health Care Conference at 12:00 p.m. Eastern Time on Tuesday, Mar....
SAN DIEGO , Feb. 25, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will present at the Cowen 40 th Annual Health Care Conference at 12:00 p.m. Eastern Time on Tuesday , Mar. 3, 2020, in Boston . Kevin Gorman , Chief Executive Officer, will present at the confe
Read more →NBIXTHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT NBIX - Q4 2019 Neurocrine Biosciences Inc Earnings Call EVENT DATE/TIME: FEBRUARY 04, 2020 / 9:30PM GMT FEBRUARY 04, 2020 / 9:30PM, NBIX - Q4 2019 Neurocrine Biosciences Inc
THOMSON REUTERS STREETEVENTS NBIX - Q4 2019 Neurocrine Biosciences Inc Earnings Call EVENT DATE/TIME: FEBRUARY 04, 2020 / 9:30PM GMT FEBRUARY 04, 2020 / 9:30PM, NBIX - Q4 2019 Neurocrine Biosciences Inc Earnings Call CORPORATE PARTICIPANTS Eiry Wyn Roberts Neurocrine Bioscie
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results INGREZZA (valbenazine) Fourth Quarter Net Product Sales of $238 Million with Approximately 42,100 TRx INGREZZA (valbenazine) Full-Year 20
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results INGREZZA (valbenazine) Fourth Quarter Net Product Sales of $238 Million with Approximately 42,100 TRx INGREZZA (valbenazine) Full-Year 2019 Net Product Sales of $753 Million with Approximately 13
Read more →NBIXNeurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the appointment of Shalini Sharp to its Board of Directors. Ms. Sharp is the Chief...
SAN DIEGO , Feb. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced the appointment of Shalini Sharp to its Board of Directors. Ms. Sharp is the Chief Financial Officer and Executive Vice President of Ultragenyx, a clinical-stage biopharmaceutica
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2019 financial results after the Nasdaq...
SAN DIEGO , Jan. 20, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it will report fourth quarter and year-end 2019 financial results after the Nasdaq market closes on Tuesday, Feb. 4, 2020 . Neurocrine will then host a conference call and
Read more →NBIXbenefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones SAN DIEGO, Jan. 12, 2020 - Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today provided an update on its business performance, including preliminary
Read more →NBIXNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today provided an update on its business performance, including preliminary net product sales results for ...
SAN DIEGO , Jan. 12, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today provided an update on its business performance, including preliminary net product sales results for 2019, and key commercial and clinical development milestones for 2020. Kevin Gorman , C
Read more →NBIXNeurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Idorsia Ltd. (SIX: IDIA) announced an amendment to the agreement that was originally signed in 2019...
SAN DIEGO and ALLSCHWIL, Switzerland , Jan. 10, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) and Idorsia Ltd. (SIX: IDIA) announced an amendment to the agreement that was originally signed in 2019 granting Neurocrine Biosciences an option to license ACT-70947
Read more →NBIXNeurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 38th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. Pacific Time (2:30 p.m....
SAN DIEGO , Jan. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the 38 th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. Pacific Time ( 2:30 p.m. Eastern Time ) on Monday, Jan. 13, 2020 , in San Francisco . Kevin Gorman , Chief Execut
Read more →NBIXNeurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced a license and collaboration agreement to develop...
SAN DIEGO and BURNABY, British Columbia , Dec. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) and Xenon Pharmaceuticals Inc. (Nasdaq: XENE ) announced a license and collaboration agreement to develop first-in-class treatments for epilepsy. Neurocrine Biosci
Read more →NBIXNeurocrine Biosciences to Present at Evercore ISI 2nd Annual HealthCONx Conference Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Evercore ISI 2nd Annual HealthCONx Conference at 8:45 a.m. Eastern Time on Tuesday,...
SAN DIEGO , Nov. 26, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the Evercore ISI 2 nd Annual HealthCONx Conference at 8:45 a.m. Eastern Time on Tuesday , Dec. 3, 2019, in Boston . Kevin Gorman , Chief Executive Officer, and Matt Abernethy ,
Read more →NBIXNeurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the Journal of Clinical Psychopharmacology1 published long-term data from the KINECT ...
SAN DIEGO , Nov. 12, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that the Journal of Clinical Psychopharmacology 1 published long-term data from the KINECT 4 Phase III, open-label study of INGREZZA ® (valbenazine) capsules, demonstrating that
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Healthcare Conferences Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Neurocrine Biosciences management will present at the following investor...
SAN DIEGO , Nov. 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that Neurocrine Biosciences management will present at the following investor conferences: The live presentations will be webcast and may be accessed on the Company's website un
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2019 Financial Results INGREZZA (valbenazine) Third Quarter Net Product Sales of $198.1 Million with Approximately 34,800 TRx Initiated KINECT-HD Phase III Study of Valbenazin
Neurocrine Biosciences Reports Third Quarter 2019 Financial Results INGREZZA (valbenazine) Third Quarter Net Product Sales of $198.1 Million with Approximately 34,800 TRx Initiated KINECT-HD Phase III Study of Valbenazine to Treat Chorea in Patients with Huntington's Disease S
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on...
SAN DIEGO , Oct. 14, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, November 4, 2019 . Neurocrine will then host a conference call and webcast to discu
Read more →NBIXNeurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg...
SAN DIEGO , Oct. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg dose of INGREZZA ® (valbenazine) capsules in reducing abnormal movements in adults with tard
Read more →NBIXNeurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses evaluating the long-term effects of once-daily 40 mg...
SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced it will present data analyses evaluating the long-term effects of once-daily 40 mg INGREZZA ® (valbenazine) in adults with tardive dyskinesia (TD), an involuntary movement disord
Read more →NBIXNeurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that David W. Boyer has joined the company's executive management team as Chief Corporate ...
SAN DIEGO , Sept. 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that David W. Boyer has joined the company's executive management team as Chief Corporate Affairs Officer. Boyer joins Neurocrine Biosciences from BGR Group, where he served as
Read more →NBIXNeurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders® Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses from its movement disorder programs, including INGREZZA®...
SAN DIEGO , Sept.17, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced it will present data analyses from its movement disorder programs, including INGREZZA ® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatm
Read more →NBIXNeurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the appointment of Leslie V. Norwalk to its Board of Directors. Ms. Norwalk formerly...
SAN DIEGO , Sept. 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced the appointment of Leslie V. Norwalk to its Board of Directors. Ms. Norwalk formerly served as Acting Administrator for the Centers for Medicare & Medicaid Services (CMS) under
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2019 Financial Results INGREZZA (valbenazine) Second Quarter Net Product Sales of $180.5 Million with Approximately 31,600 TRx FDA Accepts Opicapone New Drug Application with
Neurocrine Biosciences Reports Second Quarter 2019 Financial Results INGREZZA (valbenazine) Second Quarter Net Product Sales of $180.5 Million with Approximately 31,600 TRx FDA Accepts Opicapone New Drug Application with PDUFA Date of April 26, 2020 Congenital Adrenal Hyperpla
Read more →NBIXNeurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application...
SAN DIEGO , July 10, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for opicapone, a novel, once-daily, oral, selective catechol-O-methyltransferase (CO
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on...
SAN DIEGO , July 8, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it will report second quarter financial results after the Nasdaq market closes on Monday, July 29, 2019 . Neurocrine will then host a conference call and webcast to discuss
Read more →NBIXNeurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data from two of its movement disorder programs, including INGREZZA®...
SAN DIEGO , June 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced it will present data from two of its movement disorder programs, including INGREZZA ® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatmen
Read more →NBIXNeurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Goldman Sachs 40th Annual Global Healthcare Conference at 10:00 a.m. PT (1:00 p.m....
SAN DIEGO , June 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the Goldman Sachs 40 th Annual Global Healthcare Conference at 10:00 a.m. PT ( 1:00 p.m. ET ) on Tuesday, June 11, 2019 , in Rancho Palos Verdes, Calif. Kevin Gorman , Chief Exec
Read more →NBIXNeurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2019 Global Healthcare Conference at 10:30 a.m. ET on Thursday, June 6,...
SAN DIEGO , May 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the Jefferies 2019 Global Healthcare Conference at 10:30 a.m. ET on Thursday , June 6, 2019, in New York . Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Fina
Read more →NBIXNEUROCRINE BIOSCIENCES, INC. 2011 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 21, 2011 APPROVED BY THE STOCKHOLDERS: MAY 25, 2011 AMENDED BY THE STOCKHOLDERS: MAY 23, 2013 AMENDED BY THE STOCKHOLDER
NEUROCRINE BIOSCIENCES, INC. 2011 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 21, 2011 APPROVED BY THE STOCKHOLDERS: MAY 25, 2011 AMENDED BY THE STOCKHOLDERS: MAY 23, 2013 AMENDED BY THE STOCKHOLDERS: MAY 22, 2014 AMENDED BY THE STOCKHOLDERS: MAY 28, 2
Read more →NBIXNeurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with...
SAN DIEGO , May 20, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), demonstrating the effect of involun
Read more →NBIXNeurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it will present a new quality-of-life data analysis from RE-KINECT, the largest...
SAN DIEGO , May 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that it will present a new quality-of-life data analysis from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed possible tardive dyskinesia (
Read more →NBIXNeurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2019 at 10:00 a.m. PT (1:00 p.m. ...
SAN DIEGO , May 7, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the Bank of America Merrill Lynch Health Care Conference 2019 at 10:00 a.m. PT ( 1:00 p.m. ET ) on Tuesday, May 14, 2019 , in Las Vegas . Kevin Gorman , Chief Executive Officer, a
Read more →NBIXNeurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its support of Mental Health Month and commitment to raising awareness of tardive...
SAN DIEGO , May 6, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its support of Mental Health Month and commitment to raising awareness of tardive dyskinesia (TD), an involuntary movement disorder. 1 May marks the 70 th anniversary of Mental He
Read more →NBIXNeurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced Phase I trial results for VY-AADC from...
SAN DIEGO and CAMBRIDGE, Mass. , May 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) and Voyager Therapeutics, Inc. (NASDAQ: VYGR ) today announced Phase I trial results for VY-AADC from eight patients with Parkinson's disease who participated in the open-lab
Read more →NBIXNeurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of a data analysis from two Phase III studies of opicapone, a novel,...
SAN DIEGO , May 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced the presentation of a data analysis from two Phase III studies of opicapone, a novel, once-daily, oral, selective, peripherally-acting catechol-O-methyltransferase (COMT) inhibito
Read more →NBIXNeurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses from its movement disorder programs, including INGREZZA®...
SAN DIEGO , April 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced it will present data analyses from its movement disorder programs, including INGREZZA ® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treat
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2019 Financial Results INGREZZA (valbenazine) First Quarter Net Product Sales of $136.4 Million with Approximately 24,200 TRx Opicapone New Drug Applicat
Neurocrine Biosciences Reports First Quarter 2019 Financial Results INGREZZA (valbenazine) First Quarter Net Product Sales of $136.4 Million with Approximately 24,200 TRx Opicapone New Drug Application Submission Remains on Track for Q2 2019 Neurocrine Biosciences Plans to Mee
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2019 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended March 31, 2019 and provided an update on the...
SAN DIEGO , April 29, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended March 31, 2019 and provided an update on the launch of INGREZZA ® (valbenazine) and its clinical development programs. "We remain f
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report first quarter financial results after the Nasdaq market closes on...
SAN DIEGO , April 8, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it will report first quarter financial results after the Nasdaq market closes on Monday, April 29, 2019 . Neurocrine will then host a conference call and webcast to discuss
Read more →NBIXNeurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced positive interim results from a Phase II proof-of-concept study evaluating the safety,...
SAN DIEGO , March 12, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced positive interim results from a Phase II proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of NBI-74788, a proprietary corticotr
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Healthcare Conferences Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer,...
SAN DIEGO , March 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Financial Officer, of Neurocrine Biosciences will present at the following investor conferences: The liv
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended December 31, 2018 and provided an update on...
SAN DIEGO , Feb. 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended December 31, 2018 and provided an update on the launch of INGREZZA ® (valbenazine) and its clinical development programs. "We are ext
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results INGREZZA (valbenazine) Fourth Quarter Net Product Sales of $130.3 Million with Approximately 22,900 TRx INGREZZA (va
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results INGREZZA (valbenazine) Fourth Quarter Net Product Sales of $130.3 Million with Approximately 22,900 TRx INGREZZA (valbenazine) Full-Year 2018 Net Product Sales of $409.6 Million with Approximately
Read more →NBIXNeurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson s Disease and Friedreich s Ataxia Collaboration leverages strengths and efforts of both compani
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson s Disease and Friedreich s Ataxia Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing t
Read more →NBIXNew INGREZZA® (valbenazine) Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that a new analysis of INGREZZA® (valbenazine) capsules, published in the Journal of...
SAN DIEGO , Jan. 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that a new analysis of INGREZZA ® (valbenazine) capsules, published in the Journal of Affective Disorders 1 , demonstrated sustained improvement in tardive dyskinesia (TD) sympt
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2018 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2018 financial results after the Nasdaq...
SAN DIEGO , Jan. 15, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it will report fourth quarter and year-end 2018 financial results after the Nasdaq market closes on Tuesday, Feb. 5, 2019 . Neurocrine will then host a conference call and
Read more →NBIXNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones INGREZZA (valbenazine) Preliminary Fourth Quarter Net Product Sale
Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones SAN DIEGO, Jan. 6, 2019 - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today provided an update on its business performance, including preliminary net product
Read more →NBIXNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today provided an update on its business performance, including preliminary net product sales results for ...
SAN DIEGO , Jan. 6, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today provided an update on its business performance, including preliminary net product sales results for 2018, and key clinical development programs for 2019. Kevin Gorman, Chief Executive Offi
Read more →NBIXNeurocrine Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 37th Annual J.P. Morgan Healthcare Conference at 2:30 p.m. PT (5:30 p.m. ET) on...
SAN DIEGO , Jan. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the 37 th Annual J.P. Morgan Healthcare Conference at 2:30 p.m. PT ( 5:30 p.m. ET ) on Monday, Jan. 7, 2019 , in San Francisco . Kevin Gorman , Chief Executive Officer, will pres
Read more →NBIXNeurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced topline data from the Phase IIb T-Force GOLD study demonstrating that valbenazine did not ...
SAN DIEGO , Dec. 12, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced topline data from the Phase IIb T-Force GOLD study demonstrating that valbenazine did not meet the primary endpoint as assessed by the Yale Global Tic Severity Scale (YGTSS) in
Read more →NBIXNeurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome Company to Host C
Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome Company to Host Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT SAN DIEGO, Dec. 12, 2018
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies 2018 London Healthcare Conference Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2018 London Healthcare Conference at 11:20 a.m. GMT (6:20 a.m. ET) on...
SAN DIEGO , Nov. 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the Jefferies 2018 London Healthcare Conference at 11:20 a.m. GMT ( 6:20 a.m. ET ) on Wednesday, Nov. 14, 2018 , in London . Kevin Gorman , Chief Executive Officer, and Matt Aber
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2018 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended September 30, 2018, and provided an update on ...
SAN DIEGO , Nov. 5, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended September 30, 2018 , and provided an update on the launch of INGREZZA ® (valbenazine) and its clinical development programs. "We rema
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2018 Financial Results INGREZZA (valbenazine) Third Quarter Net Product Sales of $111.3 Million with Approximately 19,400 TRx Expanded Clinical Developme
Neurocrine Biosciences Reports Third Quarter 2018 Financial Results INGREZZA (valbenazine) Third Quarter Net Product Sales of $111.3 Million with Approximately 19,400 TRx Expanded Clinical Development Pipeline- Phase I Studies Initiated with a Novel VMAT2 Inhibitor and a First-
Read more →NBIXNeurocrine Biosciences to Present New Data Analyses on the Long-Term Effects of INGREZZA® (valbenazine) in Tardive Dyskinesia Patients with Mood Disorders at the 2018 Annual Psych Congress Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present new data analyses on the long-term effects of INGREZZA® (valbenazine)...
SAN DIEGO , Oct. 23, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced it will present new data analyses on the long-term effects of INGREZZA ® (valbenazine) capsules in adults with tardive dyskinesia (TD) and from RE-KINECT, the largest real-world
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2018 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on...
SAN DIEGO , Oct. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, Nov. 5, 2018 . Neurocrine will then host a conference call and webcast to discuss i
Read more →NBIXNeurocrine Biosciences and Jnana Therapeutics Enter Strategic Collaboration to Discover Novel Medicines to Treat Central Nervous System Disorders Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at ...
SAN DIEGO and BOSTON , Oct. 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at discovering novel small molecule therapeutics for multiple targets for centra
Read more →NBIXNeurocrine Biosciences to Present New Long-Term Data Analyses on INGREZZA® (valbenazine) at the 2018 International Congress of Parkinson's Disease and Movement Disorders Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present new long-term data analyses on INGREZZA® (valbenazine) capsules, the...
SAN DIEGO , Oct. 1, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced it will present new long-term data analyses on INGREZZA ® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dys
Read more →NBIXNeurocrine Biosciences to Present at the Morgan Stanley 16th Annual Global Healthcare Conference Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Morgan Stanley 16th Annual Global Healthcare Conference at 8:10 a.m. ET on Wednesday, ...
SAN DIEGO , Sept. 5, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the Morgan Stanley 16 th Annual Global Healthcare Conference at 8:10 a.m. ET on Wednesday, Sept. 12, 2018 , in New York City . Kevin Gorman , Chief Executive Officer of Neurocri
Read more →NBIXNeurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congress on Parkinson's Disease and Related Disorders Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data from its movement disorders programs, including additional long-term ...
SAN DIEGO , Aug. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced it will present data from its movement disorders programs, including additional long-term results for INGREZZA ® (valbenazine) capsules, the first U.S. Food and Drug Administrat
Read more →NBIXCorrected Transcript 31-Jul-2018 Neurocrine Biosciences, Inc. (NBIX) Q2 2018 Earnings Call 1-877-FACTSET w.callstreet.com Total Pages: 20 Copyright 2001-2018 FactSet CallStreet, LLC Neurocrine Biosciences, Inc. ( NBIX) Q
Exhibit 99.1 Corrected Transcript Neurocrine Biosciences, Inc. (NBIX) Q2 2018 Earnings Call CORPORATE PARTICIPANTS Kevin Charles Gorman Chief Executive Officer & Director, Neurocrine Biosciences, Inc. Jane Sorensen Executive Assistant, Neurocrine Biosciences, Inc. Matthe
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2018 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended June 30, 2018, and provided an update on the...
SAN DIEGO , July 31, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended June 30, 2018 , and provided an update on the launch of INGREZZA ® (valbenazine), the U.S. Food and Drug Administration (FDA) approva
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2018 Financial Results INGREZZA (valbenazine) Second Quarter Net Product Sales of $96.9 Million with Approximately 16,700 TRx ORILISSA (elagolix), the F
Neurocrine Biosciences Reports Second Quarter 2018 Financial Results INGREZZA (valbenazine) Second Quarter Net Product Sales of $96.9 Million with Approximately 16,700 TRx ORILISSA (elagolix), the First FDA-Approved Oral Treatment for Moderate to Severe Endometriosis Pain in Ov
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2018 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on...
SAN DIEGO , July 10, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it will report second quarter financial results after the Nasdaq market closes on Tuesday, July 31, 2018 . Neurocrine will then host a conference call and webcast to discus
Read more →NBIXChief Executive Officer of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a San Diego based biotechnology company focused on neurological and endocrine related disorders, is...
SAN DIEGO , June 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), a San Diego based biotechnology company focused on neurological and endocrine related disorders, is proud to announce that Kevin Gorman , Ph.D., Chief Executive Officer of Neurocrine Bioscience
Read more →NBIXNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch 2018 Healthcare Conference at 8:40 a.m. PT (11:40 a.m....
SAN DIEGO , May 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the Bank of America Merrill Lynch 2018 Healthcare Conference at 8:40 a.m. PT ( 11:40 a.m. ET ) on Tuesday, May 15, 2018 , in Las Vegas, Nevada . Kevin Gorman , CEO of Neurocrine B
Read more →NBIXNeurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with...
SAN DIEGO , May 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), providing valuable insight into the
Read more →NBIXNeurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting Neurocrine Biosciences Inc. (NASDAQ: NBIX) today announced that it will present new data from RE-KINECT, the largest real-world screening study to...
SAN DIEGO , May 2, 2018 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASDAQ: NBIX ) today announced that it will present new data from RE-KINECT, the largest real-world screening study to date of patients with clinician confirmed possible tardive dyskinesia (TD). This study is de
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2018 Financial Results INGREZZA (valbenazine) First Quarter Net Product Sales of $71.1 Million with Approximately 12,500 TRx Strong INGREZZA Demand Leads
Biosciences Reports First Quarter 2018 Financial Results INGREZZA (valbenazine) First Quarter Net Product Sales of $71.1 Million with Approximately 12,500 TRx Strong INGREZZA Demand Leads to Expansion of Sales Force Increased Investment in Tourette Syndrome Clinical Program w
Read more →NBIXNeurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug...
SAN DIEGO , April 25, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that once-daily INGREZZA ® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), improved TD sym
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report first quarter financial results after the Nasdaq market closes on...
SAN DIEGO , April 23, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it will report first quarter financial results after the Nasdaq market closes on Monday, April 30, 2018 . Neurocrine will then host a conference call and webcast to discus
Read more →NBIXNeurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new data for once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and...
SAN DIEGO , April 18, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that new data for once-daily INGREZZA ® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), wi
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Healthcare Conferences Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, CEO of Neurocrine Biosciences, will present at the following investor...
SAN DIEGO , March 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that Kevin Gorman , CEO of Neurocrine Biosciences, will present at the following investor conferences: The live presentations will be webcast and may be accessed on the Company
Read more →NBIXNeurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson s Disease Based on Existing Pivotal Clinical Trial Data Neurocrine Plans to File the NDA During the First Half of 20
Biosciences Will File New Drug Application for Opicapone for Parkinson s Disease Based on Existing Pivotal Clinical Trial Data Neurocrine Plans to File the NDA During the First Half of 2019 SAN DIEGO, Feb. 14, 2018 Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology c
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the fourth quarter and year-end of 2017, and provided an update ...
SAN DIEGO , Feb. 13, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the fourth quarter and year-end of 2017, and provided an update on the launch of INGREZZA ® (valbenazine) and clinical development programs for 2018.
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018 INGREZZA (valbenazine) Fourth Quarter Net Product Sales of $64.5 Million with
Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor INGREZZA (valbenazine) Fourth Quarter Net Product Sales of $64.5 Million with Approximately 9,100 TRx INGREZZA Net Product Sales of $116.6 Million with Approximately 14,900 TRx Since
Read more →NBIXNeurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare Conference Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Leerink Partners 7th Annual Global Healthcare Conference at 11:30 a.m. ET on...
SAN DIEGO , Feb. 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the Leerink Partners 7 th Annual Global Healthcare Conference at 11:30 a.m. ET on Thursday , Feb. 15, 2018, in New York City . Kevin Gorman , CEO of Neurocrine Biosciences, will
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2017 financial results after the Nasdaq...
SAN DIEGO , Feb. 6, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it will report fourth quarter and year-end 2017 financial results after the Nasdaq market closes on Tuesday, Feb. 13, 2018 . Neurocrine will then host a conference call and
Read more →NBIXNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones Total Preliminary Revenue for the Fourth Quarter of 2017 was Approximately $94
Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones SAN DIEGO, Jan. 7, 2018 - Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced an update on its business performance, including preliminary sales results for 2017
Read more →NBIXNeurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that...
SAN DIEGO , Jan. 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), a biotechnology company focused on neurological and endocrine related disorders, today announced that Christopher O'Brien , M.D., Chief Medical Officer, has notified the Company he plans to ret
Read more →NBIXNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced an update on its business performance, including preliminary sales results for 2017 and...
SAN DIEGO , Jan. 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced an update on its business performance, including preliminary sales results for 2017 and key program initiatives for 2018. Kevin Gorman , CEO of Neurocrine, will discuss these upd
Read more →NBIXNeurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 36th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT (6:00 p.m. ET) on...
SAN DIEGO , Jan. 2, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the 36th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT ( 6:00 p.m. ET ) on Monday, Jan. 8, 2018 , in San Francisco . Kevin Gorman , CEO of Neurocrine Biosciences, will
Read more →NBIXNeurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference at 11:00 a.m....
SAN DIEGO , Dec. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference at 11:00 a.m. ET on Thursday , Dec. 14, 2017, in New York City . Timothy P. Coughlin , Vice President
Read more →NBIXNeurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new long-term data from the KINECT 4 Phase III open-label study demonstrate that...
SAN DIEGO , Dec. 4, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that new long-term data from the KINECT 4 Phase III open-label study demonstrate that once-daily INGREZZA ® (valbenazine) capsules, the first FDA approved treatment for adults wi
Read more →NBIXNeurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new long-term data from the open-label KINECT 4 Phase III study of INGREZZA®...
SAN DIEGO , Nov. 29, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that new long-term data from the open-label KINECT 4 Phase III study of INGREZZA ® (valbenazine) capsules, the first FDA approved treatment for adults with tardive dyskinesia (T
Read more →NBIXNeurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 29th Annual Piper Jaffray Healthcare Conference at 12:00 p.m. ET on Tuesday, Nov. 28, ...
SAN DIEGO , Nov. 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the 29th Annual Piper Jaffray Healthcare Conference at 12:00 p.m. ET on Tuesday, Nov. 28, 2017 , in New York City . Timothy P. Coughlin , Vice President Finance of Neurocrine Bi
Read more →NBIXNeurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that...
SAN DIEGO , Nov. 20, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), a biotechnology company focused on neurological and endocrine related disorders, today announced that Matt Abernethy is joining the executive management team as Chief Financial Officer (CFO).
Read more →NBIXNeurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the full manuscript of the long-term safety and efficacy data from the blinded...
SAN DIEGO , Nov. 14, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that the full manuscript of the long-term safety and efficacy data from the blinded KINECT 3 Phase III extension study evaluating INGREZZA ® (valbenazine) capsules for the treat
Read more →NBIXINGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences Association Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that INGREZZA® (valbenazine) capsules, the first FDA approved product indicated for the...
SAN DIEGO , Nov. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that INGREZZA ® (valbenazine) capsules, the first FDA approved product indicated for the treatment of adults with tardive dyskinesia (TD), a condition characterized by uncontroll
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies 2017 London Healthcare Conference Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2017 London Healthcare Conference at 11:20 a.m. GMT (6:20 a.m. ET) on...
SAN DIEGO , Nov. 8, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the Jefferies 2017 London Healthcare Conference at 11:20 a.m. GMT ( 6:20 a.m. ET ) on Thursday, Nov. 16, 2017 , in London . Kevin Gorman , CEO of Neurocrine Biosciences, will pre
Read more →NBIXNeurocrine to Present Data on the Patient Impact of Tardive Dyskinesia from the RE-KINECT Study at the 2017 Neuroscience Education Institute Congress Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that data for INGREZZA® (valbenazine) capsules, the first FDA approved treatment for...
SAN DIEGO , Nov. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that data for INGREZZA ® (valbenazine) capsules, the first FDA approved treatment for adults with tardive dyskinesia (TD), will be presented at the 2017 Neuroscience Education In
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2017 Results - INGREZZA (valbenazine) Net Product Sales of $45.8 Million for Initial Full Quarter of Commercialization as the First U.S. Food and Drug Administration Approved
Neurocrine Biosciences Reports Third Quarter 2017 Results - INGREZZA (valbenazine) Net Product Sales of $45.8 Million for Initial Full Quarter of Commercialization as the First U.S. Food and Drug Administration Approved Product for the Treatment of Tardive Dyskinesia - Elagoli
Read more →NBIXNeurocrine Biosciences to Present at the Credit Suisse 26th Annual Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Credit Suisse ...
SAN DIEGO , Oct. 31, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, will be presenting at the Credit Suisse 26th Annual Healthcare Conference in Scottsdale, Arizona. The live presentation takes
Read more →NBIXNeurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA® in Children and Adolescents with Tourette Syndrome Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase IIb clinical trial, T-Force GOLD, for INGREZZA®...
SAN DIEGO , Oct. 25, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has initiated a Phase IIb clinical trial, T-Force GOLD, for INGREZZA ® (valbenazine), a novel selective vesicular monoamine transporter 2 (VMAT2) inhibitor, in children
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2017 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report third quarter 2017 results after the Nasdaq market close on...
SAN DIEGO , Oct. 24, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report third quarter 2017 results after the Nasdaq market close on November 1, 2017 . Neurocrine will then host a live conference call and webcast to discu
Read more →NBIXNeurocrine Granted FDA Orphan Drug Designation for Valbenazine for the Treatment of Pediatric Patients With Tourette Syndrome Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that valbenazine, a novel selective vesicular monoamine transporter 2 (VMAT2), has been...
SAN DIEGO , Oct. 23, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that valbenazine, a novel selective vesicular monoamine transporter 2 (VMAT2), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the tr
Read more →NBIXNeurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD) Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved an 80 mg INGREZZA®...
SAN DIEGO , Oct. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that the U.S. Food and Drug Administration (FDA) has approved an 80 mg INGREZZA ® (valbenazine) capsule strength to be used for the treatment of adults with tardive dyskinesia (T
Read more →NBIXNeurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congress Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced today upcoming poster presentations at the 2017 Annual Psych Congress featuring data from the...
SAN DIEGO , Sept. 15, 2017 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASDAQ: NBIX ) announced today upcoming poster presentations at the 2017 Annual Psych Congress featuring data from the RE-KINECT study outlining the real-world presence and impact of tardive dyskinesia (TD) o
Read more →NBIXNeurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Morgan...
SAN DIEGO , Sept. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, will be presenting at the Morgan Stanley 15 th Annual Global Healthcare Conference in New York City . The live presentation t
Read more →NBIXNeurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Baird 2017...
SAN DIEGO , Aug. 30, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, will be presenting at the Baird 2017 Global Healthcare Conference in New York City . The live presentation takes place on Wed
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2017 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2017, highlighted by the successful...
SAN DIEGO , Aug. 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended June 30, 2017 , highlighted by the successful regulatory approval and commercial launch of INGREZZA ® (valbenazine) capsules in tardiv
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2017 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report second quarter 2017 results after the Nasdaq market close on ...
SAN DIEGO , July 28, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report second quarter 2017 results after the Nasdaq market close on August 3, 2017 . Neurocrine will then host a live conference call and webcast to discus
Read more →NBIXNeurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced that Julie...
SAN DIEGO , July 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), a biotechnology company focused on neurological and endocrine related disorders, announced that Julie Cooke is joining as Chief People Officer in September 2017 and will be a member of the Man
Read more →NBIXNeurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Goldman Sachs ...
SAN DIEGO , June 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, will be presenting at the Goldman Sachs 38 th Annual Global Healthcare Conference in Rancho Palos Verdes, CA. The live present
Read more →NBIXNeurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st International Congress of Parkinson's Disease and Movement Disorders Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the upcoming presentation of three posters at the 21st International Congress of...
SAN DIEGO , June 2, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today the upcoming presentation of three posters at the 21st International Congress of Parkinson's Disease and Movement Disorders (MDS), including data from the KINECT 3 Phase III exte
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies 2017 Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Jefferies...
SAN DIEGO , June 1, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2017 Global Healthcare Conference in New York City . The live presentation takes place on
Read more →NBIXNeurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the initial Phase II Tourette syndrome T-Force GREEN study of...
SAN DIEGO , May 23, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that the initial Phase II Tourette syndrome T-Force GREEN study of INGREZZA ® (valbenazine), a small molecule VMAT2 inhibitor, did not meet its primary endpoint. The pre-specifie
Read more →NBIXNeurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at the 2017 American Psychiatric Association Annual Meeting Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced today the upcoming presentation at the American Psychiatric Association (APA) Annual Meeting of...
SAN DIEGO , May 18, 2017 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASDAQ: NBIX ) announced today the upcoming presentation at the American Psychiatric Association (APA) Annual Meeting of pharmacokinetic data, as well as long-term data from the KINECT 3 Phase III extension stu
Read more →NBIXNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Bank of...
SAN DIEGO , May 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas . The live presentation takes
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2017 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2017, highlighted by the launch of...
SAN DIEGO , May 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended March 31, 2017 , highlighted by the launch of INGREZZA ® (valbenazine) capsules in tardive dyskinesia as well as other recent progress
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report first quarter 2017 results after Nasdaq market close on...
SAN DIEGO , May 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report first quarter 2017 results after Nasdaq market close on Tuesday, May 9, 2017 . Neurocrine will then host a live conference call and webcast to discuss
Read more →NBIXNeurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior Notes Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed its previously announced private offering of $517.5 million...
SAN DIEGO , May 2, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has completed its previously announced private offering of $517.5 million aggregate principal amount of its 2.25% convertible senior notes due 2024 (the "notes"), which in
Read more →NBIXNeurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the pricing of its offering of $450.0 million aggregate principal amount of 2.25%...
SAN DIEGO , April 26, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today the pricing of its offering of $450.0 million aggregate principal amount of 2.25% convertible senior notes due 2024 (the "notes"). The notes will be sold in a private offering
Read more →NBIXNeurocrine Announces Proposed Convertible Senior Notes Offering Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate...
SAN DIEGO , April 25, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offeri
Read more →NBIXNeurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that long-term safety and efficacy data from the KINECT 3 Phase III extension study of...
SAN DIEGO , April 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that long-term safety and efficacy data from the KINECT 3 Phase III extension study of INGREZZA ™ (valbenazine) capsules for the treatment of adults with tardive dyskinesia wil
Read more →NBIXNeurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved INGREZZATM (valbenazine)...
SAN DIEGO , April 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that the U.S. Food and Drug Administration (FDA) has approved INGREZZA TM (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). INGREZZA, a novel, se
Read more →NBIXNeurocrine Announces FDA Approval of INGREZZA™ (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) (with multimedia) Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved INGREZZA™ (valbenazine)...
SAN DIEGO , April 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that the U.S. Food and Drug Administration (FDA) has approved INGREZZA ™ (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). INGREZZA, a novel, sel
Read more →NBIXNeurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurologic, psychiatric and endocrine related disorders, announced...
SAN DIEGO , March 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), a biotechnology company focused on neurologic, psychiatric and endocrine related disorders, announced today that positive results from the Kinect 3 Phase III study of INGREZZA (valbenazine) f
Read more →NBIXNeurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter and full year 2016, and highlighted recent progress...
SAN DIEGO , Feb. 14, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter and full year 2016, and highlighted recent progress on its pipeline. "2016 was a very successful year for Neurocrine highlighted by the fi
Read more →NBIXNeurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and BIAL today announced that they have entered into an exclusive licensing agreement for the development ...
SAN DIEGO and PORTO, Portugal , Feb. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) and BIAL today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North America . ONGENTYS ® (op
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter 2016 results after the Nasdaq market...
SAN DIEGO , Feb. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its fourth quarter 2016 results after the Nasdaq market closes on Tuesday, February 14, 2017 . Neurocrine will then host a live conference call and w
Read more →NBIXNeurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the top-line results from the Company's Phase II T-Forward study of INGREZZA™...
SAN DIEGO , Jan. 17, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today the top-line results from the Company's Phase II T-Forward study of INGREZZA ™ (valbenazine), a highly-selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibit
Read more →NBIXNeurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced that...
SAN DIEGO , Jan. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), a biotechnology company focused on neurological and endocrine related disorders, announced that David-Alexandre "DA" Gros M.D. has joined the executive management team as President and Chief Op
Read more →NBIXNeurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA), after further review of the INGREZZA™...
SAN DIEGO , Jan. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that the U.S. Food and Drug Administration (FDA), after further review of the INGREZZA ™ (valbenazine) New Drug Application (NDA), has decided to cancel the Psychopharmacologic D
Read more →NBIXNeurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , Jan. 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the 35 th Annual J.P. Morgan Healthcare Conference in San Francisco . The live presentatio
Read more →NBIXNeurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced today that...
SAN DIEGO , Dec. 21, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), a biotechnology company focused on neurological and endocrine related disorders, announced today that Timothy P. Coughlin will be stepping down from his position as Chief Financial Officer in
Read more →NBIXNeurocrine Biosciences to Present at the 2016 BMO Capital Markets Prescription for Success Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , Dec. 7, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the 2016 BMO Capital Markets Prescription for Success Healthcare Conference in New York Cit
Read more →NBIXNeurocrine Biosciences Announces INGREZZA™ (valbenazine) Long-Term Data to be Presented at the 55th Annual Meeting of the American College of Neuropsychopharmacology Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced today that...
SAN DIEGO , Dec. 5, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), a biotechnology company focused on neurological and endocrine related disorders, announced today that two abstracts representing additional data from several clinical trials of the investigatio
Read more →NBIXNeurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA™ (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug...
SAN DIEGO , Nov. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data included in the New Drug Application (NDA) of INGREZZA TM (
Read more →NBIXNeurocrine Biosciences to Present at the 28th Annual Piper Jaffray Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , Nov. 21, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the 28 th Annual Piper Jaffray Healthcare Conference in New York City . The live presenta
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies 2016 London Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , Nov. 10, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 London Healthcare Conference in London . The live presentation takes p
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2016 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2016. For the third quarter of...
SAN DIEGO , Nov. 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended September 30, 2016 . For the third quarter of 2016, the Company reported a net loss of $36.9 million , or $0.43 loss per share, compar
Read more →NBIXNeurocrine Biosciences to Present at the Credit Suisse 25th Annual Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , Oct. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the Credit Suisse 25 th Annual Healthcare Conference in Scottsdale, AZ. The live presenta
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2016 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2016 results after the Nasdaq market...
SAN DIEGO , Oct. 26, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its third quarter 2016 results after the Nasdaq market closes on Wednesday, November 2, 2016 . Neurocrine will then host a live conference call and
Read more →NBIXNeurocrine Announces INGREZZA™ (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia has been Accepted for Priority Review by U.S. FDA Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New ...
SAN DIEGO , Oct. 11, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for INGREZZA TM (valbenazine) for the treatment of tardive dyski
Read more →NBIXNeurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , Sept. 7, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the Morgan Stanley Healthcare Conference in New York City . The live presentation takes p
Read more →NBIXNeurocrine Biosciences to Present at the Baird 2016 Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , Sept. 1, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the Baird 2016 Healthcare Conference in New York City . The live presentation takes place
Read more →NBIXNeurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the...
SAN DIEGO , Aug. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name "INGREZZA™" for the Company's once-daily vesicular monoamine transporter 2 (VMAT
Read more →NBIXNeurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...
SAN DIEGO , Aug. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-daily dosing of valbenazine in treating tardive dyskinesia. "This is
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2016 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2016. For the second quarter of 2016, ...
SAN DIEGO , Aug. 3, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended June 30 , 2016. For the second quarter of 2016, the Company reported a net loss of $40.3 million , or $0.46 loss per share, compared t
Read more →NBIXNeurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase II clinical trial for NBI-98854 (valbenazine), a highly...
SAN DIEGO , July 28, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has initiated a Phase II clinical trial for NBI-98854 (valbenazine), a highly selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in children,
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2016 results after the Nasdaq market...
SAN DIEGO , July 27, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its second quarter 2016 results after the Nasdaq market closes on Wednesday, August 3, 2016 . Neurocrine will then host a live conference call and w
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , June 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 Healthcare Conference in New York City . The live presentation takes pl
Read more →NBIXNeurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of...
SAN DIEGO , May 20, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of Directors effective just prior to the 2016 Annual Meeting of Shareholders. Mr. Mitchell has
Read more →NBIXNeurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association's 2016 Annual Meeting in Atlanta Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2...
SAN DIEGO , May 6, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatri
Read more →NBIXNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , May 6, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas . The live prese
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2016 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2016. For the first quarter of 2016, ...
SAN DIEGO , May 5, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended March 31, 2016 . For the first quarter of 2016, the Company reported a net loss of $19.3 million , or $0.22 loss per share, compared to
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2016 results after the Nasdaq market...
SAN DIEGO , April 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its first quarter 2016 results after the Nasdaq market closes on Thursday, May 5, 2016 . Neurocrine will then host a live conference call and webca
Read more →NBIXNeurocrine Biosciences to Present at the Deutsche Bank 41st Annual Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , April 27, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the Deutsche Bank 41 st Annual Health Care Conference in Boston . The live presentation
Read more →NBIXNeurocrine Biosciences to Present at the Barclays Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , March 9, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the Barclays Global Healthcare Conference in Miami Beach . The live presentation takes pl
Read more →NBIXNeurocrine Biosciences Announces the Acceptance of Three Scientific Abstracts for Valbenazine (NBI-98854) at the 68th Annual Meeting of the American Academy of Neurology in Vancouver April 2016 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that on April 20, 2016, data from the Phase III Kinect 3 study of valbenazine (NBI-98854) ...
SAN DIEGO , March 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that on April 20, 2016 , data from the Phase III Kinect 3 study of valbenazine (NBI-98854) for tardive dyskinesia will be presented during a plenary session at the American Acad
Read more →NBIXNeurocrine Biosciences to Present at the Cowen and Company 36th Annual Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , March 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the Cowen and Company 36 th Annual Health Care Conference in Boston . The live presentati
Read more →NBIXNeurocrine Biosciences Reports Year-End 2015 Results and Provides Investor Update for 2016 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter and year ended December 31, 2015. For the fourth...
SAN DIEGO , Feb. 11, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter and year ended December 31, 2015 . For the fourth quarter of 2015, the Company reported a net loss of $29.3 million , or $0.34 loss per sh
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2015 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2015 results after the...
SAN DIEGO , Feb. 8, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its fourth quarter and year-end 2015 results after the Nasdaq market closes on Thursday, February 11, 2016. Neurocrine will then host a live conferen
Read more →NBIXNeurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , Feb. 3, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the Leerink Partners 5 th Annual Global Healthcare Conference in New York City . The live
Read more →NBIXNeurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase II clinical trial for NBI-98854 (valbenazine), a highly...
SAN DIEGO , Feb. 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has initiated a Phase II clinical trial for NBI-98854 (valbenazine), a highly selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in children an
Read more →NBIXNeurocrine Biosciences to Present at the 34th Annual J.P. Morgan Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Jan. 4, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 34 th Annual J.P. Morgan Healthcare Conference in San Francisco. T
Read more →NBIXNeurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has successfully completed the Phase Ib T-Force study of NBI-98854 (valbenazine), ...
SAN DIEGO , Dec. 16, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has successfully completed the Phase Ib T-Force study of NBI-98854 (valbenazine), a once-daily, highly selective, small molecule Vesicular Monoamine Transporter 2 (VMAT2
Read more →NBIXNeurocrine Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , Nov. 25, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the 27th Annual Piper Jaffray Healthcare Conference in New York . The live presentation t
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies Autumn 2015 Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the ...
SAN DIEGO , Nov. 11, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies Autumn 2015 Global Healthcare Conference in London . The live presentation
Read more →NBIXNeurocrine Biosciences Announces Expansion of its Clinical Pipeline Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced today that...
SAN DIEGO , Nov. 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), a biotechnology company focused on neurological and endocrine related disorders, announced today that the Company's Investigational New Drug (IND) application, filed with the U.S. Food and Drug
Read more →NBIXNeurocrine Biosciences to Present at Credit Suisse's 24th Annual Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at...
SAN DIEGO , Nov. 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and CEO of Neurocrine Biosciences, will be presenting at Credit Suisse's 24 th Annual Healthcare Conference in Scottsdale, AZ. The live presentatio
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2015 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2015. For the third quarter of...
SAN DIEGO , Oct. 29, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended September 30, 2015 . For the third quarter of 2015, the Company reported a net loss of $34.4 million , or $0.40 loss per share, compa
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2015 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2015 financial results after the Nasdaq...
SAN DIEGO , Oct. 22, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its third quarter 2015 financial results after the Nasdaq market closes on Thursday, October 29 , 2015. Neurocrine will then host a live conference
Read more →NBIXNeurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has expanded the clinical efforts for NBI-98854 (Valbenazine), a highly selective ...
SAN DIEGO , Oct. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has expanded the clinical efforts for NBI-98854 (Valbenazine), a highly selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, by initiating a Pha
Read more →NBIXNeurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically ...
SAN DIEGO , Oct. 8, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled t
Read more →NBIXNeurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has appointed George J. Morrow to its Board of Directors. Mr. Morrow has over...
SAN DIEGO , Sept. 30, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has appointed George J. Morrow to its Board of Directors. Mr. Morrow has over three decades of global pharmaceutical commercial operations leadership experience with Am
Read more →NBIXNeurocrine Biosciences Announces the Appointment of Dr. Alfred W. Sandrock to its Board of Directors Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has appointed Alfred W. Sandrock, Jr., M.D., Ph.D. to its Board of Directors...
SAN DIEGO , Sept. 3, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has appointed Alfred W. Sandrock, Jr. , M.D., Ph.D. to its Board of Directors effective immediately. Dr. Sandrock is the current Group Senior Vice President and Chief Me
Read more →NBIXNeurocrine Biosciences to Present at the Baird 2015 Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting...
SAN DIEGO , Sept. 2, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Tim Coughlin , Chief Financial Officer of Neurocrine Biosciences, will be presenting at the Baird 2015 Healthcare Conference in New York City . The live presentation takes
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2015 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2015. For the second quarter of 2015, ...
SAN DIEGO , July 29, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended June 30, 2015 . For the second quarter of 2015, the Company reported a net loss of $24.0 million , or $0.28 loss per share, compared
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2015 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2015 financial results after the Nasdaq...
SAN DIEGO , July 22, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its second quarter 2015 financial results after the Nasdaq market closes on Wednesday, July 29 , 2015. Neurocrine will then host a live conference c
Read more →NBIXNeurocrine Biosciences Provides Update on NBI-77860 Program for Congenital Adrenal Hyperplasia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has suspended two planned clinical studies of the Company's CRF antagonist...
SAN DIEGO , June 8, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has suspended two planned clinical studies of the Company's CRF antagonist NBI-77860. "Out of an abundance of caution, we halted the implementation of these studies and
Read more →NBIXNeurocrine Biosciences, Inc. Announces Appointment of Eric Benevich as Chief Commercial Officer Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Eric Benevich has joined the company as Chief Commercial Officer. We are very...
SAN DIEGO , June 2, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that Eric Benevich has joined the company as Chief Commercial Officer. "We are very pleased to welcome Eric to the Neurocrine team as our Chief Commercial Officer," said Kevin G
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies 2015 Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , May 27, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2015 Healthcare Conference in New York City . The live p
Read more →NBIXNeurocrine Biosciences to Host Analyst and Investor Day in New York City on May 21, 2015 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will host an Analyst and Investor Day at the New York Palace Hotel in New York...
SAN DIEGO , May 12, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it will host an Analyst and Investor Day at the New York Palace Hotel in New York City on Thursday May 21, 2015 from 12:00 p.m. to 3:30 p.m. ET ( 9:00 a.m. to 12:30 p.m. PT
Read more →NBIXNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2015 Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , May 8, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Veg
Read more →NBIXNeurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Dr. Bill Aurora has joined the company as Vice President, Medical Affairs. We are...
SAN DIEGO , May 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that Dr. Bill Aurora has joined the company as Vice President, Medical Affairs. "We are very pleased to welcome Dr. Bill Aurora to the Neurocrine team as our Vice President, Medi
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2015 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, ...
SAN DIEGO , April 30, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended March 31, 2015 . For the first quarter of 2015, the Company reported a net loss of $1.2 million , or $0.01 loss per share, compared
Read more →NBIXNeurocrine Biosciences to Present at the Deutsche Bank 40th Annual Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , April 30, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Deutsche Bank 40 th Annual Health Care Conference in Boston . Th
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2015 results before the Nasdaq market...
SAN DIEGO , April 23, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its first quarter 2015 results before the Nasdaq market opens on Thursday, April 30, 2015 . Neurocrine will then host a live conference call and we
Read more →NBIXNeurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has entered into an exclusive collaboration and licensing agreement for the...
SAN DIEGO , March 31, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other sele
Read more →NBIXNeurocrine Biosciences to Present at the Barclays Global Healthcare Conference Live Audio Webcast Will be on March 10, 2015 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , March 3, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Barclays Global Healthcare Conference in Miami. The live presenta
Read more →NBIXNeurocrine Biosciences to Present at Cowen and Company's 35th Annual Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Feb. 24, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at Cowen and Company's 35 th Annual Health Care Conference in Boston. Th
Read more →NBIXNeurocrine Biosciences, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the underwriters of its previously announced public offering have exercised in full...
SAN DIEGO , Feb. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 1,041,600 shares of Neurocrine's common stock at
Read more →NBIXNeurocrine Biosciences, Inc. Prices Public Offering of Common Stock Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of its underwritten public offering of 6,944,000 shares of its common stock...
SAN DIEGO , Feb. 19, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the pricing of its underwritten public offering of 6,944,000 shares of its common stock at a price to the public of $36.00 per share. The gross proceeds to Neurocrine from this
Read more →NBIXNeurocrine Biosciences, Inc. Announces Proposed Public Offering of $225 Million of Common Stock Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has commenced an underwritten public offering of shares of its common stock to...
SAN DIEGO , Feb. 17, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $225 million . In connection with this offering,
Read more →NBIXNeurocrine Biosciences Reports Year-End 2014 Results and Provides Investor Update for 2015 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter and year ended December 31, 2014. For the fourth...
SAN DIEGO , Feb. 9, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter and year ended December 31, 2014 . For the fourth quarter of 2014, the Company reported a net loss of $19.4 million , or $0.26 loss per sha
Read more →NBIXNeurocrine Biosciences to Present at the 2015 Leerink Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting...
SAN DIEGO , Feb. 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Tim Coughlin , Chief Financial Officer of Neurocrine Biosciences, will be presenting at the 2015 Leerink Global Healthcare Conference in New York City . The live presentati
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2014 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2014 results after the...
SAN DIEGO , Feb. 2, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its fourth quarter and year-end 2014 results after the Nasdaq market closes on Monday, February 9, 2015 . Neurocrine will then host a live conference
Read more →NBIXNeurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic Congenital Adrenal Hyperplasia at ENDO 2015 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the steering committee of ENDO 2015 has selected the abstract of their recently...
SAN DIEGO , Jan. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860 in classic congenital adrenal hyperplasia for an oral
Read more →NBIXNeurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal Hyperplasia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, ...
SAN DIEGO , Jan. 16, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (
Read more →NBIXNeurocrine Biosciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference eurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Jan. 8, 2015 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 33 rd Annual J.P. Morgan Healthcare Conference in San Francisco. Th
Read more →NBIXNeurocrine Biosciences Announces Expansion of its Clinical Pipeline Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, ...
SAN DIEGO , Dec. 10, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has entered clinical trials for the treatment of classic congenital adrenal hyperplasia
Read more →NBIXNeurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Dec. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 25 th Annual Oppenheimer Healthcare Conference in New York City. T
Read more →NBIXNeurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Nov. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at two investor conferences next week. On December 2 at 11:40am Eastern
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Nov. 12, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in London . The live
Read more →NBIXNeurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Darin Lippoldt has joined the executive management team as Chief Legal Officer. We...
SAN DIEGO , Nov. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that Darin Lippoldt has joined the executive management team as Chief Legal Officer. "We are very pleased to welcome Darin Lippoldt to the Neurocrine leadership team as our Chie
Read more →NBIXNeurocrine Biosciences to Present at the Nomura Biotechnology Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Nov. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Nomura Biotechnology Conference in Boston. The live presentation t
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2014 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2014. For the third quarter of...
SAN DIEGO , Nov. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended September 30, 2014 . For the third quarter of 2014, the Company reported a net loss of $15.9 million , or $0.21 loss per share, compar
Read more →NBIXNeurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
SAN DIEGO , Oct. 30, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskines
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2014 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2014 financial results after the Nasdaq...
SAN DIEGO , Oct. 27, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its third quarter 2014 financial results after the Nasdaq market closes on Monday, November 3, 2014 . Neurocrine will then host a live conference ca
Read more →NBIXNeurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase III clinical trial (Kinect 3 Study) of its proprietary...
SAN DIEGO , Oct. 20, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has initiated a Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854. The design of the Kinect 3 Study is a
Read more →NBIXNeurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a clinical trial of NBI-98854, a proprietary small molecule...
SAN DIEGO , Oct. 2, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Toure
Read more →NBIXNeurocrine Biosciences, Inc. Announces Appointment of Malcolm Lloyd-Smith as Chief Regulatory Officer Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Malcolm Lloyd-Smith has joined the executive management team as Chief Regulatory...
SAN DIEGO , Oct. 1, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that Malcolm Lloyd-Smith has joined the executive management team as Chief Regulatory Officer. "We are very pleased to welcome Malcolm Lloyd-Smith to the Neurocrine leadership t
Read more →NBIXNeurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Sept. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Morgan Stanley Global Healthcare Conference in New York City. The
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2014 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2014. For the second quarter of 2014, ...
SAN DIEGO , Aug. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended June 30, 2014 . For the second quarter of 2014, the Company reported a net loss of $13.4 million , or $0.18 loss per share, compared t
Read more →NBIXNeurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2014 financial results after the Nasdaq...
SAN DIEGO , July 29, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its second quarter 2014 financial results after the Nasdaq market closes on Wednesday, August 6, 2014 . Neurocrine will then host a live conference
Read more →NBIXNeurocrine Biosciences Presenting NBI-98854 Scientific Abstracts And Posters At The International Parkinson And Movement Disorder Society's 18th Annual Congress Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that on June 11, 2014, two scientific posters associated with its study of NBI-98854 in...
SAN DIEGO , June 11, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that on June 11, 2014 , two scientific posters associated with its study of NBI-98854 in Phase IIb clinical trials of tardive dyskinesia patients, will be presented at the 2014
Read more →NBIXNeurocrine Biosciences To Present At The Jefferies 2014 Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , May 29, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in New York City. The
Read more →NBIXNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , May 8, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Veg
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2014 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2014. For the first quarter of 2014, ...
SAN DIEGO , April 30, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended March 31 , 2014. For the first quarter of 2014, the Company reported a net loss of $11.8 million , or $0.17 loss per share, compared
Read more →NBIXNeurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2014 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2014 financial results after the Nasdaq...
SAN DIEGO , April 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its first quarter 2014 financial results after the Nasdaq market closes on Wednesday, April 30, 2014 . Neurocrine will then host a live conference
Read more →NBIXNeurocrine Biosciences To Present At The 26th Annual Roth Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , March 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26 th Annual Roth Conference in Laguna. The live presentation tak
Read more →NBIXNeurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Feb. 27, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 34 th Annual Health Care Conference in Boston.
Read more →NBIXNeurocrine Biosciences, Inc. Prices Public Offering of Common Stock Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at ...
SAN DIEGO , Feb. 26, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $17.75 per share. The gross proceeds to Neurocrine from this o
Read more →NBIXNeurocrine Biosciences Announces NBI-98854 Scientific Presentations at the International Parkinson and Movement Disorder Society's 18th Annual Congress Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that two NBI-98854 scientific abstracts have been accepted for the scientific program at...
SAN DIEGO , Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that two NBI-98854 scientific abstracts have been accepted for the scientific program at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders, to be held June
Read more →NBIXNeurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten...
SAN DIEGO , Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Neurocrine will also grant to the underwri
Read more →NBIXNeurocrine Biosciences To Present At The Leerink Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting...
SAN DIEGO , Feb. 7, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Tim Coughlin , Chief Financial Officer of Neurocrine Biosciences, will be presenting at the Leerink Global Healthcare Conference in New York City. The live presentation tak
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter And Year End 2013 Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2013. For the fourth...
SAN DIEGO , Feb. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter and year ended December 31, 2013 . For the fourth quarter of 2013, the Company reported a net loss of $10.6 million , or $0.16 loss per sha
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2013 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2013 financial results after ...
SAN DIEGO , Feb. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its fourth quarter and year-end 2013 financial results after the Nasdaq market closes on Thursday, February 6, 2014. Neurocrine will then host a live
Read more →NBIXNeurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, in development for tardive dyskinesia,...
SAN DIEGO , Jan. 9, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that NBI-98854, a small molecule VMAT2 inhibitor, in development for tardive dyskinesia, showed an excellent safety profile and a clinically meaningful reduction in tardive dyski
Read more →NBIXNeurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, showed a statistically significant and...
SAN DIEGO , Jan. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that NBI-98854, a small molecule VMAT2 inhibitor, showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms in the Phase IIb Kinect 2
Read more →NBIXNeurocrine Biosciences To Present At Oppenheimer's 24th Annual Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Dec. 4, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at Oppenheimer's 24 th Annual Healthcare Conference in New York City. The
Read more →NBIXNeurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Nov. 26, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at two investor conferences next week. On December 3 at 2:15pm Eastern T
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2013 Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended September 30, 2013. For the third quarter of...
SAN DIEGO , Oct. 29, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended September 30, 2013 . For the third quarter of 2013, the Company reported a net loss of $11.1 million , or $0.17 loss per share, compa
Read more →NBIXNeurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2013 financial results after the Nasdaq...
SAN DIEGO , Oct. 22, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its third quarter 2013 financial results after the Nasdaq market closes on Tuesday, October 29, 2013. Neurocrine will then host a live conference ca
Read more →NBIXNeurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the 50mg dose of NBI-98854, a small molecule VMAT2 inhibitor in development for...
SAN DIEGO , Sept. 9, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that the 50mg dose of NBI-98854, a small molecule VMAT2 inhibitor in development for tardive dyskinesia, did not meet the primary endpoint in the Phase IIb Kinect study while th
Read more →NBIXNeurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that the second Phase III pivotal trial to evaluate elagolix for the treatment of...
SAN DIEGO , Aug. 29, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that the second Phase III pivotal trial to evaluate elagolix for the treatment of endometriosis has been initiated by AbbVie. This second Phase III trial is similar in design to
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2013 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2013. For the second quarter of 2013, ...
SAN DIEGO , July 25, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended June 30, 2013 . For the second quarter of 2013, the Company reported a net loss of $12.2 million , or $0.18 loss per share, compared
Read more →NBIXNeurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2013 financial results after the Nasdaq...
SAN DIEGO , July 18, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its second quarter 2013 financial results after the Nasdaq market closes on Thursday, July 25, 2013 . Neurocrine will then host a live conference ca
Read more →NBIXNeurocrine Announces Completion Of Enrollment Into Kinect Study For Treatment Of Tardive Dyskinesia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed recruitment in the Phase IIb clinical trial (Kinect Study) of its...
SAN DIEGO , July 1, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has completed recruitment in the Phase IIb clinical trial (Kinect Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The final subject will
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , May 29, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2013 Global Healthcare Conference in New York. The live
Read more →NBIXNeurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , May 23, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Deutsche Bank 38 th Annual dbAccess Health Care Conference in Bosto
Read more →NBIXNeurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , May 9, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Veg
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2013 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2013. For the first quarter of 2013, ...
SAN DIEGO , May 2, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended March 31, 2013 . For the first quarter of 2013, the Company reported net loss of $12.1 million , or $0.18 loss per share, compared to a
Read more →NBIXNeurocrine Biosciences Announces Conference Call And Webcast To Present First Quarter 2013 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2013 financial results after the Nasdaq...
SAN DIEGO , April 26, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its first quarter 2013 financial results after the Nasdaq market closes on Thursday, May 2, 2013. Neurocrine will then host a live conference call
Read more →NBIXNeurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , April 24, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Needham 12 th Annual Healthcare Conference in New York City. The
Read more →NBIXNeurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids ...
SAN DIEGO , March 27, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagon
Read more →NBIXNeurocrine Biosciences To Present At The 25th Annual Roth Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting...
SAN DIEGO , March 11, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Tim Coughlin , Chief Financial Officer of Neurocrine Biosciences, will be presenting at the 25 th Annual Roth Conference in Laguna Niguel. The live presentation takes pla
Read more →NBIXNeurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting...
SAN DIEGO , Feb. 27, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Tim Coughlin , Chief Financial Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 33 rd Annual Health Care Conference in Boston. The live prese
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2012. For the fourth...
SAN DIEGO , Feb. 8, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter and year ended December 31, 2012 . For the fourth quarter of 2012, the Company reported net income of $9.5 million , or $0.14 per fully dil
Read more →NBIXNeurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting...
SAN DIEGO , Feb. 6, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Tim Coughlin , Chief Financial Officer of Neurocrine Biosciences, will be presenting at the Leerink Swann Global Healthcare Conference 2013 in New York City. The live prese
Read more →NBIXNeurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2012 financial results...
SAN DIEGO , Feb. 1, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its fourth quarter and year-end 2012 financial results before the Nasdaq market opens on Friday, February 8, 2013. Neurocrine will then host a live c
Read more →NBIXNeurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that two additional patents have been granted related to the Company's proprietary...
SAN DIEGO , Jan. 23, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that two additional patents have been granted related to the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2) NBI-98854. European Patent Number 2,081,9
Read more →NBIXNeurocrine Announces Start Of Second Phase IIb Study Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase IIb clinical trial (Kinect 2 Study) of its proprietary...
SAN DIEGO , Dec. 18, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has initiated a Phase IIb clinical trial (Kinect 2 Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this six-week Phase II
Read more →NBIXNeurocrine Biosciences To Present At Deutsche Bank's 2012 dbAccess BioFEST Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting...
SAN DIEGO , Nov. 27, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Tim Coughlin , Chief Financial Officer of Neurocrine Biosciences, will be presenting at Deutsche Bank's 2012 dbAccess BioFEST in Boston. The live presentation takes place
Read more →NBIXNeurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Nov. 20, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 24 th Annual Piper Jaffray Healthcare Conference in New York . Th
Read more →NBIXNeurocrine Biosciences To Present At Lazard Capitalmarket's 9th Annual Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Nov. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at Lazard Capital Market's 9 th Annual Healthcare Conference in New York.
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2012 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter and nine months ended September 30, 2012. For the...
SAN DIEGO , Oct. 31, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter and nine months ended September 30, 2012 . For the third quarter of 2012, the Company reported a net loss of $3.1 million , or $0.05 loss p
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2012 financial results after the Nasdaq...
SAN DIEGO , Oct. 24, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its third quarter 2012 financial results after the Nasdaq market closes on Wednesday, October 31, 2012 . Neurocrine will then host a live conference
Read more →NBIXNeurocrine Announces Start Of Phase IIb Study Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase IIb clinical trial (Kinect Study) of its proprietary...
SAN DIEGO , Oct. 1, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has initiated a Phase IIb clinical trial (Kinect Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this twelve-week Phase II
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2012 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2012. For the second quarter of 2012, ...
SAN DIEGO , July 31, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended June 30, 2012 . For the second quarter of 2012, the Company reported a net loss of $0.5 million , or $0.01 loss per share, compared t
Read more →NBIXNeurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2012 financial results after the Nasdaq...
SAN DIEGO , July 25, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its second quarter 2012 financial results after the Nasdaq market closes on Tuesday, July 31, 2012 . Neurocrine will then host a live conference cal
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , May 29, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2012 Global Healthcare Conference in New York. The live
Read more →NBIXNeurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with...
SAN DIEGO , May 17, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two y
Read more →NBIXNeurocrine Biosciences To Present At The Deutsche Bank 37th Annual Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , May 4, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Deutsche Bank 37th Annual Health Care Conference in Boston. The liv
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2012 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2012. For the first quarter of 2012, ...
SAN DIEGO , May 2, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended March 31, 2012 . For the first quarter of 2012, the Company reported net loss of $0.9 million , or $0.01 loss per share, compared with
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2012 financial results after the Nasdaq...
SAN DIEGO , April 25, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its first quarter 2012 financial results after the Nasdaq market closes on Wednesday, May 2, 2012. Neurocrine will then host a live conference call
Read more →NBIXElagolix Endometriosis Phase III Trials on Track to Commence in Second Quarter 2012 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that the United States Food and Drug Administration (FDA) has responded to the Special...
SAN DIEGO , March 27, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that the United States Food and Drug Administration (FDA) has responded to the Special Protocol Assessment (SPA) filed with the FDA on the design of the Phase III program for e
Read more →NBIXNeurocrine Biosciences to Present at the 11th Annual Needham Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , March 27, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 11 th Annual Needham Healthcare Conference in New York. The live
Read more →NBIXNeurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced efficacy and safety results from a Phase II trial of NBI-98854 in 37 tardive dyskinesia...
SAN DIEGO , March 26, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced efficacy and safety results from a Phase II trial of NBI-98854 in 37 tardive dyskinesia patients. For the final analysis, data from one site was removed due to the inconsistent
Read more →NBIXNeurocrine Biosciences to Present at The 24th Annual Roth Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Vice President and Chief Financial Officer of Neurocrine Biosciences,...
SAN DIEGO , March 7, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Tim Coughlin , Vice President and Chief Financial Officer of Neurocrine Biosciences, will be presenting at the 24th Annual Roth Conference in Laguna Niguel. The live prese
Read more →NBIXNeurocrine Biosciences to Present at the 32nd Annual Cowen Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Feb. 29, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 32nd Annual Cowen Health Care Conference in Boston. The live pres
Read more →NBIXNeurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Feb. 21, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Citi 2012 Global Health Care Conference in New York. The live pre
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter and Year End 2011 Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2011. For the fourth...
SAN DIEGO , Feb. 8, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter and year ended December 31, 2011 . For the fourth quarter of 2011, the Company reported net income of $1.3 million , or $0.02 per fully dil
Read more →NBIXNeurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Feb. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 14th Annual BIO CEO & Investor Conference in New York. The live pr
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast To Present Fourth Quarter and Year-End 2011 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2011 financial results after ...
SAN DIEGO , Feb. 2, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its fourth quarter and year-end 2011 financial results after the Nasdaq market closes on Wednesday, February 8, 2012. Neurocrine will then host a liv
Read more →NBIXNeurocrine Biosciences, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the closing of the sale of 1,425,000 shares of its common stock pursuant to the exercise...
SAN DIEGO , Jan. 30, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the closing of the sale of 1,425,000 shares of its common stock pursuant to the exercise in full of an option to purchase such shares granted to the underwriters of Neurocrine's
Read more →NBIXNeurocrine Biosciences Announces The FDA Has Granted Fast Track Designation For VMAT2 Inhibitor NBI-98854 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that its VMAT2 inhibitor product candidate, NBI-98854, has been granted Fast Track...
SAN DIEGO , Jan. 25, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that its VMAT2 inhibitor product candidate, NBI-98854, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of neuroleptic-in
Read more →NBIXNeurocrine Biosciences, Inc. Prices Public Offering of Common Stock Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 9,500,000 shares of its common stock at ...
SAN DIEGO , Jan. 19, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the pricing of an underwritten public offering of 9,500,000 shares of its common stock at a price to the public of $8.10 per share. The gross proceeds to Neurocrine from this of
Read more →NBIXNeurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell shares of its common stock in an underwritten public offering....
SAN DIEGO , Jan. 18, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. and Deutsche Bank Securities Inc. are acting as joint book-r
Read more →NBIXNeurocrine Mourns the Passing of Founder and Board Member Wylie Vale, Ph.D. Neurocrine Biosciences, Inc. (Nasdaq: NBIX) is sad to announce that its academic founder and member of the Board of Directors, Wylie W. Vale, Ph.D....
SAN DIEGO , Jan. 7, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) is sad to announce that its academic founder and member of the Board of Directors, Wylie W. Vale , Ph.D. passed away earlier this week. He was a thoughtful leader with an incredible scientific m
Read more →NBIXNeurocrine Biosciences to Present at the 30th Annual J.P. Morgan Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Jan. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 30th Annual J. P. Morgan Healthcare Conference at the Westin St. Fr
Read more →NBIXNeurocrine Biosciences to Present at the 23rd Annual Piper Jaffray Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Nov. 23, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 23rd Annual Piper Jaffray Health Care Conference in New York. The
Read more →NBIXNeurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference SAN DIEGO, Nov. 3, 2011 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of...
SAN DIEGO , Nov. 3, 2011 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 2011 Credit Suisse Annual Health Care Conference in Phoenix . The live presentat
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2011 Results Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2011. For the third quarter of...
SAN DIEGO , Oct. 31, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended September 30, 2011 . For the third quarter of 2011, the Company reported net income of $31.4 million , or $0.56 per fully diluted sh
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2011 financial results after the Nasdaq...
SAN DIEGO , Oct. 26, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its third quarter 2011 financial results after the Nasdaq market closes on Monday, October 31, 2011. Neurocrine will then host a live conference cal
Read more →NBIXNeurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has achieved its second milestone in its collaboration with Abbott for elagolix...
SAN DIEGO , Oct. 4, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that it has achieved its second milestone in its collaboration with Abbott for elagolix and next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists. The Compan
Read more →NBIXNeurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that an elagolix podium presentation has been accepted for the scientific program at the...
SAN DIEGO , Sept. 27, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that an elagolix podium presentation has been accepted for the scientific program at the 2011 Annual Meeting of the American Society for Reproductive Medicine, to be held Octob
Read more →NBIXNeurocrine Biosciences Announces That VMAT 2 Program Begins Enrollment in Second Phase II Clinical Trial Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a second Phase II clinical trial of its proprietary Vesicular...
SAN DIEGO , Sept. 19, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has initiated a second Phase II clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this second Phase II study is a
Read more →NBIXNeurocrine Biosciences to Present at the UBS Global Life Sciences Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Sept. 13, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the UBS Global Life Sciences Conference in New York . The live prese
Read more →NBIXNeurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that Abbott has started a Phase II clinical trial to evaluate elagolix, a next-generation...
SAN DIEGO , Sept. 13, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that Abbott has started a Phase II clinical trial to evaluate elagolix, a next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonist, in the treatment of uterine
Read more →NBIXNeurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Sept. 1, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Stifel Nicolaus 2011 Healthcare Conference in Boston . The live p
Read more →NBIXNeurocrine Biosciences Reports Second Quarter 2011 Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended June 30, 2011. For the second quarter of...
SAN DIEGO , July 28, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended June 30, 2011 . For the second quarter of 2011, the Company reported net income of $2.0 million , or $0.04 per share, compared to a n
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2011 financial results after the Nasdaq...
SAN DIEGO , July 21, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its second quarter 2011 financial results after the Nasdaq market closes on Thursday, July 28, 2011 . Neurocrine will then host a live conference ca
Read more →NBIXNeurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of...
SAN DIEGO , June 23, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NB
Read more →NBIXNeurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that three elagolix presentations have been accepted for the scientific program at 2011...
SAN DIEGO , June 16, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that three elagolix presentations have been accepted for the scientific program at 2011 World Congress on Endometriosis, to be held September 4-7, 2011 in Montpellier, France .
Read more →NBIXNeurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , May 31, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2011 Global Healthcare Conference in New York . The live
Read more →NBIXNeurocrine Biosciences Reports First Quarter 2011 Results Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended March 31, 2011. For the first quarter of...
SAN DIEGO , May 3, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the quarter ended March 31, 2011 . For the first quarter of 2011, the Company reported net income of $2.9 million , or $0.05 per share, compared with a n
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2011 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2011 financial results after the Nasdaq...
SAN DIEGO , April 29, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its first quarter 2011 financial results after the Nasdaq market closes on Tuesday, May 3, 2011 . Neurocrine will then host a live conference call
Read more →NBIXNeurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , April 27, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Deutsche Bank 36th Annual Healthcare Conference in Boston . The
Read more →NBIXNeurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor eurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed the dosing and preliminary assessment of the initial cohort of...
SAN DIEGO , April 5, 2011 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor
Read more →NBIXNeurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , March 30, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 10th Annual Needham Healthcare Conference in New York City . The
Read more →NBIXNeurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , March 8, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Roth 23rd Annual OC Growth Stock Conference in Laguna Niguel, CA.
Read more →NBIXNeurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , March 2, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen & Co. 31st Annual Health Care Conference in Boston . The li
Read more →NBIXNeurocrine Biosciences to Present at Citi's 2011 Global Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Feb. 23, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at Citi's 2011 Global Health Care Conference in New York . The live pres
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2010 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2010 financial results after ...
SAN DIEGO , Feb. 3, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its fourth quarter and year-end 2010 financial results after the Nasdaq market closes on Thursday, February 10, 2011 . Neurocrine will then host a li
Read more →NBIXNeurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter and year ended December 31, 2010. For the fourth...
SAN DIEGO , Feb. 10, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced its financial results for the quarter and year ended December 31, 2010 . For the fourth quarter of 2010, the Company reported net income of $2.5 million , or $0.05 per basic sh
Read more →NBIXNeurocrine Biosciences to Present at the 22nd Annual Piper Jaffray Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Nov. 23, 2010 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 22nd Annual Piper Jaffray Health Care Conference in New
Read more →NBIXNeurocrine Biosciences Announces Successful Completion of Daisy PETAL Study Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from the open-label portion of the six month Phase II Daisy PETAL study (901...
SAN DIEGO , Nov. 22, 2010 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced results from the open-label portion of the six month Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Horm
Read more →NBIXNeurocrine Biosciences Reports Third Quarter 2010 Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended September 30, 2010. For the third quarter of...
SAN DIEGO , Oct. 28 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced its financial results for the quarter ended September 30, 2010 . For the third quarter of 2010, the Company reported net income of $3.3 million , or $0.06 per share, compar
Read more →NBIXNeurocrine Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Oct. 26 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Oppenheimer 21st Annual Healthcare Conference in New York . The live pr
Read more →NBIXNeurocrine Biosciences Announces That VMAT2 Program Will Move Into Phase II Clinical Trials Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has successfully completed a second Phase I clinical trial of its proprietary...
SAN DIEGO , Oct. 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it has successfully completed a second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The positive results of this Ph
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2010 financial results after the Nasdaq...
SAN DIEGO , Oct. 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will report its third quarter 2010 financial results after the Nasdaq market closes on Thursday, October 28, 2010 . Neurocrine will then host a live confere
Read more →NBIXNeurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line efficacy and safety results from a Phase II clinical trial utilizing...
SAN DIEGO , Sept. 14 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently expe
Read more →NBIXNeurocrine Biosciences to Present at Two Upcoming Conferences on September 16 and September 22 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will...
SAN DIEGO , Sept. 9 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Stifel Nicolaus 2010 Healthcare Conference in Boston and at the UBS Glob
Read more →Competitive Position
How NBIX ranks across every disease it competes inCompetitive Position is a premium feature
See how NBIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial